14/01/2022

| Date | Journal | Title | Study type | Country | Authors | Link | Trial identifier | Intervention | Main question |
|---|---|---|---|---|---|---|---|---|---|
| 21-Dec-21 | Ann Intern Med. | COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System | RWD trial | USA | Ioannou, G.N, et al. | https://www.acpjournals.org/doi/10.7326/M21-3256 | U.S. Department of Veterans Affairs health care system - | Moderna or Pfizer–BioNTech COVID-19 vaccine | To determine the effectiveness of messenger RNA COVID-19 vaccines in racially and ethnically diverse, elderly populations with high comorbidity burden. |
| 20-Dec-21 | Lancet | Two-dose ChAdOx1 nCoV 19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil | Cohorts of adults who received two doses of ChAdOx1 nCoV-19 | Brazil/UK | Katikireddi S.V., et al. | https://linkinghub.elsevier.com/retrieve/pii/S0140673621027549 | CONEP approval number 4.921.308 (Brazil), National Research Ethics Service Committee, Southeast Scotland 02 (reference number: 12/SS/0201 (UK) | ChAdOx1 nCoV-19 vaccine | To investigate the association between time since two doses of ChAdOx1 nCoV-19 vaccine and risk of severe COVID-19 outcomes in Scotland (where delta was dominant), with comparative analyses in Brazil (where delta was uncommon). |
| 16-Dec-21 | BMJ | SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study | RWD trial - 12 years or older | Denmark | Husby A., et al. | https://www.bmj.com/content/375/bmj-2021-068665 | NA | mRNA vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) | To investigate the association between SARS-CoV-2 vaccination and myocarditis or myopericarditis. |
| 16-Dec-21 | Lancet Respir Med. | Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial | RCT - 2 phase | UK | Fisher B.A, et al | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00460-4/fulltext | ISRCTN 40580903 | namilumab and infliximab | To assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating factor inhibitor) and infliximab (a tumour necrosis factor inhibitor) in hospitalised patients with COVID-19, to prioritise agents for phase 3 trials. |
| 15-Dec-21 | NEJM | Efficacy and Safety of NVX CoV2373 in Adults in the United States and Mexico | RCT - 3 phase | USA | Dunkle, L.M, et al. | https://www.nejm.org/doi/10.1056/NEJMoa2116185 | NCT04611802 | NVX-CoV2373 - adjuvanted, recombinant spike protein nanoparticle vaccine. | To prove the clinical efficacy for the prevention of COVID19 in phase 2b–3 trials in the UK and South Africa. Primary objective vaccine efficacy against RT PCR confimed cases occurring at least 7 days after the second dose. Vaccine efficacy against moderate-to-severe disease and against different variants was also assessed. |
| 07-Dec-21 | Science Transl Med. | Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV 2 experienced individuals. | Prospective cohort study | USA | Samanovic M.I., et al. | https://www.science.org/doi/10.1126/scitranslmed.abi8961 | NYU Institutional Review Board (protocols 18-02035 and 18-02037) | two-dose BNT162b2 mRNA vaccine | To evaluate longitudinal immune responses to two-dose BNT162b2 mRNA vaccination in 15 adults who had experienced COVID-19, compared to 21 adults who did not have prior COVID-19. |
| 23-Dec-21 | The Lancet Infectious Diseases | Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial | RCT | Multinational (USA, Denmark, Poland, Switzerland) | ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group | https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00751-9/fulltext#%20 | NCT04501978 | sotrovimab and BRII-196 plus BRII-198 | Assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab and BRII-196 plus BRII-198) for adults admitted to hospital for COVID-19 |
| 23-Dec-21 | The Lancet | Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial | RCT | Multinational (Argentina, Chile, Mexico, Pakistan, Russia) | Halperin et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02753-7/fulltext#%20 | NCT04526990 | Ad5-nCoV vaccine | efficacy and safety of Ad5-nCoV vaccine |
| 10-Nov-21 | Intensive Care Medicine | Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial | Secondary analysis of RCT | Denmark | Granholm et al. | https://link.springer.com/article/10.1007%2Fs00134-021-06573-1 | EudraCT, 2020-003363-25, NCT04509973 | dexamethasone | Analysed outcome data of RCT using Bayesian models with various sensitivity to assess the differences between dexamethasone 12 vs. 6 mg in COVID patients |
| Jan-22 | International Journal of Infectious Diseases | Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial | RCT | Japan | Asano et al. | https://www.sciencedirect.com/science/article/pii/S1201971221008183?via%3Dihub | NCT04568031 | ChAdOx1 nCoV-19 vaccine | Immunigenicity and safety of ChAdOx1 nCoV-19 vaccine in Japanese adults |
| 23-Nov-21 | The Lancet Infectious Diseases | Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study | Case-control study | India | Devashish et al. | https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00674-5/fulltext# | NA | NA | The effectiveness of BBV152 against symptomatic RT-PCR-confirmed SARS-CoV-2 infection |
| 25-Nov-21 | The Lancet Infectious Diseases | Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses | Case-control study | India | Thiruvengadam et al. | https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00680-0/fulltext#%20 | NA | NA | Effectiveness of the ChAdOx1 nCoV-19 vaccine, predominantly against the delta (B.1.617.2) variant, in addition to the cellular immune response to vaccination |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 1-Dec-21 | The Lancet Respiratory Medicine | Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial | RCT | Multinational | Temesgen et al. | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00494-X/fulltext | NCT04351152 | Lenzilumab | To assess efficacy and safety of lenzilumab in treating COVID-19 beyond available treatments |
| 2-Dec-21 | The Lancet | Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial | RCT | UK | Munro et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02717-3/fulltext | ISRCTN 73765130 | Covid vaccines | Reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 or BNT162b2 |
| 7-Dec-21 | The Lancet Infectious Diseases | Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials | RCT | China | Zeng et al. | https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00681-2/fulltext#%20 | NCT04352608 and NCT04383574 | CoronaVac vaccine | Immunogenicity and safety of a third dose of CoronaVac, in healthy adults aged 18 years and older |
| 08-Dec-21 | NEJM | 62b2 Vaccine Booster and Mortality Due to Cov | Real world data for all members of Clalit Health Services, CHS data repositories | Israel | Arbel R., et al. | https://www.nejm.org/doi/10.1056/NEJMoa2115624 | NA | BNT162b2 booster | To gather evidence regarding the effectiveness of the booster in lowering mortality due to Covid-19 over the Delta wave |
| 08-Dec-21 | NEJM | Protection against Covid 19 by BNT162b2 Booster across Age Groups | Real world data, Israel Ministry of Health database | Israel | Bar-On Y.M., et al. | https://www.nejm.org/doi/10.1056/NEJMoa2115926 | NA | BNT162b2 Booster | To gather evidence on protection against Covid-19 by BNT162b2 booster to persons in younger age groups |
| 03-Dec-21 | JAMA | Immunogenicity of Extended mRNA SARS CoV-2 Vaccine Dosing Intervals | cohort study - paramedics | Canada | Grunau B., et al. | https://jamanetwork.com/journals/jama/fullarticle/2786992 | NA | Extended mRNA SARS CoV-2 Vaccine Dosing Intervals | To investigate the immunogenicity of extended mRNA vaccine dosing intervals |
| 25-Oct-21 | BMJ | Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study | Test negative design study, | Israel | Israel A., et al | https://www.bmj.com/content/375/bmj-2021-067873 | Electronic health records of a large state mandated healthcare organisation, Israel. | Pfizer-BioNTech BNT162b2 mRNA vaccine | To determine whether time elapsed since the second injection of the Pfizer-BioNTech BNT162b2 mRNA vaccine was significantly associated with the risk of covid-19 infection after vaccination in people who received two vaccine injections. |
| 23-Oct-21 | Science | Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial | RCT | USA | Gilbert P.B., et al. | Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial (science.org) | NCT04470427 | mRNA-1273 COVID-19 vaccine | To evaluate the efficacy of mRNA-1273 COVID-19 vaccine |
| 23-Oct-21 | Nature | A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity | phase I vaccine trial | Germany | Heitmann J.S., et al. | https://www.nature.com/articles/s41586-021-04232-5 | NCT04954469 | CoVac-1 | Phase I open-label trial on 36 participants aged 18 to 80 years, who received one single subcutaneous CoVac-1 vaccination. Primary endpoint: safety analysed until day 56. Main secondary endpoint: immunogenicity in terms of CoVac-1-induced T-cell response, analysed as until day 28 and in the follow-up until month 3. |
| 23-Oct-21 | ancet Infect Dis | Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo controlled, phase 2b/3 trial | RCT | International | Kremsner P. G., et al | https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00677-0/fulltext | NCT04652102, and EudraCT, 2020–003998–22, | CVnCoV SARS-CoV-2 mRNA vaccine | To analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate. |
| 19-Oct-21 | Clin Infect Dis. | Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial | RCT | Malaysia | Chuan Huan C., et al | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab962/6432025?searchresult=1 | NCT04818320 | favipiravir | To determine its effect in preventing disease progression from non-hypoxia to hypoxia among high risk COVID-19 patients. |
| 17-Nov-21 | The Lancet Rheumatology | Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial | RCT | France | The CORIMUNO-19 Collaborative group | https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00315-5/fulltext | NCT04324073 | sarilumab | Effect of sarilumab in moderate to severe COVID-19 pneumonia |
| 17-Nov-21 | The Lancet Respiratory Medicine | Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial | RCT | UK | Toback et al. | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00409-4/fulltext | NCT04583995 | NVX-CoV2373 vaccine and influenza vaccines | Safety, immunogenicity, and efficacy of NVX-CoV2373 when co-administered with licensed seasonal influenza vaccines |
| 17-Nov-21 | The Lancet | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial | RCT | UK | RECOVERY Collaborative Group | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01825-0/fulltext | NCT04381936 | Efficacy and safety of aspirin in patients admitted to hospital with COVID-19 | Efficacy and safety of aspirin in patients admitted to hospital with COVID-19 |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 23-Nov-21 | Scientific reports | Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis | systematic review and meta-analysis | Israel | Rotshild et al. | https://pubmed.ncbi.nlm.nih.gov/34815503/ | NA | COVID-19 vaccines | Compare the efficacy of COVID-19 vaccines to prevent symptomatic and severe disease in adults and prevent symptomatic COVID-19 among eldery |
| 23-Nov-21 | American Journal of Respiratory and Critical Care Medicine | Prostacyclin in Mechanically Ventilated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized, Clinical Trial | RCT | Denmark | Johansson et al. | https://www.atsjournals.org/doi/10.1164/rccm.202108-1855OC?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed | NCT 04420741; EudraCT Identifier: 2020-001296-33 | Prostacyclin | Effect of prostacyclin infusion in mechanically ventilated SARSCoV-2 infected patients with severe endotheliopathy |
| 22-Nov-21 | JAMA | Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19<br>A Randomized Clinical Trial | RCT | USA | Clemency et al. | https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786012 | NCT04377711 | Ciclesonide | Efficacy of the inhaled steroid ciclesonide in reducing the time to alleviation of all COVID-19–related symptoms among nonhospitalized participants with symptomatic COVID-19 infection |
| Dec-21 | E Clinical Medicine | Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial | RCT | Switzerland | Labhardt et al. | https://pubmed.ncbi.nlm.nih.gov/34778734/ | NCT04364022 | lopinavir/ritonavir | Is lopinavir/ritonavir effective in post-exposure prophylaxis? |
| 28-Oct-21 | NEJM | Early Treatment for Covid 19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab | RCT | USA | Gupta A., et al. | https://www.nejm.org/doi/10.1056/NEJMoa2107934 | NCT04545060. opens in new tab | Sotrovimab | To evaluate the safety and efficacy of sotrovimab. If Sotrovimab can reduce the risk of disease progression in high-risk patients with mild-to-moderate Covid-19. |
| 26-Oct-21 | Science Transl Med. | GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults | Phase I vaccine trial | Italy | Lanini S., et al. | https://www.science.org/doi/10.1126/scitranslmed.abj1996 | NCT04528641 | GRAd COV2 vaccine | To describe a COVID-19 vaccine based on a replication-defective gorilla adenovirus expressing the stabilized pre-fusion SARS-CoV-2 spike protein, named GRAd-COV2; and asses the safety and immunogenicity of a single-dose regimen of this vaccine in healthy younger and older adults to select the appropriate dose for each age group |
| 25-Oct-21 | Nature Medicine | Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection | self-controlled case series study | UK | Patone M et al. | https://www.nature.com/articles/s41591-021-01556-7 | NA | ChAdOx1nCoV-19 or BNT162b2 | To investigate hospital admissions from neurological complications in the 28 days after a first dose of ChAdOx1nCoV-19 (n = 20,417,752) or BNT162b2 (n = 12,134,782), and after a SARS-CoV-2-positive test (n = 2,005,280). |
| 14-Sep-21 | Science | Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells | samples from the phase 1 mRNA-1273 study | USA | Mateus J. et al. | https://www.science.org/doi/10.1126/science.abj9853 | NCT04283461 | Moderna messenger RNA (mRNA)–1273 vaccine | To examine vaccine-specific CD4+ T cell, CD8+ T cell, binding antibody, and neutralizing antibody responses to the 25-mg Moderna messenger RNA (mRNA)–1273 vaccine over the course of 7 months after immunization. |
| 21-Oct-21 | JAMA | Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia<br>The COVID STEROID 2 Randomized Trial | RCT | Denmark | Perner A., et al. | https://jamanetwork.com/journals/jama/fullarticle/2785529 | NCT04509973 | 12 mg vs 6 mg of Dexamethasone | To assess the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia |
| 18-Oct-21 | Lancet Respir Med | Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial | RCT | UK | RECOVERY Collaborative Group | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00435-5/fulltext | NCT04381936 | colchicine | To evaluate the efficacy and safety of colchicine in patients admitted to hospital with COVID-19 |
| 16-Oct-21 | Cell | Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine | cohort study | Thailand | Payne R. P., et al. | https://www.cell.com/cell/pdf/S0092-8674(21)01221-6.pdf?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867421012216%3Fshowall%3Dtrue | NA | BNT162b2 mRNA vaccine | To demonstrate the impact of extended dosing intervals on BNT162b2 mRNA vaccine effectiveness against infection. |
| 15-Oct-21 | NEJM | Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines | (#2021P000344) and the parent biorepository study (#2020P000361) | USA | Collier A.Y., et al. | https://www.nejm.org/doi/10.1056/NEJMc2115596 | (#2021P000344) and the parent biorepository study (#2020P000361) | two-dose BNT162b2 vaccine (n=31), the two dose mRNA-1273 vaccine | To report comparative kinetics of humoral and cellular immune responses elicited by the two-dose BNT162b2 vaccine (n=31), the two dose mRNA-1273 vaccine (n=22), and the one-dose Ad26.COV2.S vaccine (n=8) up to 8 months after vaccination. |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 4-Oct-21 | JAMA | Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19<br>A Randomized Clinical Trial | RCT | UK | Estcourt et al. | https://jamanetwork.com/journals/jama/fullarticle/2784914?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=etoc&utm_term=110221 | NCT02735707 | Convalescent plasma | To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19 |
| 27-Oct-21 | Lancet Glob Health | Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial | RCT | Brazil | Reis et al. | https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext | NCT04727424 | Fluvoxamine | Efficacy of fluvoxamine versus placebo in preventing hospitalisation |
| 29-Oct-21 | The Lancet Respiratory Medicine | Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial | RCT | Belgium | Declercq et al. | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00377-5/fulltext | NCT04330638, EudraCT 2020-001500-41 | anti-IL1 and anti-IL6 drugs (anakinra, siltuximab, tocilizumab) | Whether blockade of the IL-6 or IL-1 pathway shortened the time to clinical improvement in patients with COVID-19, hypoxic respiratory failure, and signs of systemic cytokine release syndrome |
| 29-Oct-21 | The Lancet | Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study | Observational study | Israel | Barda et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02249-2/fulltext | NA | NA | evaluate the effectiveness of a third dose of the BNT162b2 mRNA vaccine for preventing severe COVID-19 outcomes |
| 11-Nov-21 | The Lancet Respiratory Medicine | Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial | RCT | France | Mazeraud et al. | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00440-9/fulltext | NCT04350580 | Immunoglobulins | whether intravenous immunoglobulins (IVIG) could improve outcomes by reducing inflammation-mediated lung injury |
| 11-Nov-21 | The Lancet | Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial | RCT | UK | Lazarus et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02329-1/fulltext | ISRCTN14391248 | ChAdOx1 or BNT162b2 vaccine | Safety of concomitant administration of ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine |
| 11-Nov-21 | The Lancet | Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial | RCT | India | Ella et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02000-6/fulltext | , NCT04641481 | BBV152 | clinical efficacy of BBV152 vaccine against SARS-CoV-2 |
| 24-Sep-21 | Clinical Trial | A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia | RCT | Indonesia | Fadlyana et al. | https://pubmed.ncbi.nlm.nih.gov/34620531/ | NCT04508075 | Sinovac Vaccine | Efficacy, safety, and immunogenicity of an inactivated (SARS-CoV-2) vaccine |
| 1-Oct-21 | Plos Medicine | Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial | RCT | USA | Formica et al. | https://pubmed.ncbi.nlm.nih.gov/34597298/ | NCT04368988 | NVX-CoV2373 vaccine | Identification of dosing regimen of NVX-CoV2373 vaccine |
| 05-Oct-21 | Nature Commun. | Efficacy of ChAdOx1 nCoV 19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil | post hoc analysis of phase III vaccine trial | Brazil/UK | Costa Clemens S.A., et al. | https://www.nature.com/articles/s41467-021-25982-w | ISRCTN89951424 - post hoc analysis | ChAdOx1 nCoV 19 (AZD1222) vaccine | To investigate the efficacy of ChAdOx1 nCoV-19 (AZD1222) against symptomatic COVID-19 in a post-hoc exploratory analysis of a Phase 3 randomised trial in Brazil. |
| 30-Sep-21 | Nature Medicine | Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors | RCT | USA | Shroff R.T. et al. | Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors \| Nature Medicine | NCT04936997 | BNT162b2 mRNA vaccine | To compare the immune responses to the BNT162b2 mRNA Coronavirus Disease 2019 vaccine in patients with solid tumors (n = 53) who were on active cytotoxic anti-cancer therapy to a control cohort of participants without cancer (n = 50). |
| 30-Sep-21 | Science Transl Med | AZD1222/ChAdOx1 nCoV 19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire | RCT | USA | Swanson P.A., et al. | https://www.science.org/doi/10.1126/scitranslmed.abj7211 | NCT04400838 | AZD1222 (ChAdOx1 nCoV-19) vaccine | To characterize CD4+ and CD8+ T cell responses induced by AZD1222 (ChAdOx1 nCoV-19) vaccination in peripheral blood mononuclear cells (PBMCs) from 296 unique vaccine recipients aged 18 to 85 years who enrolled in the phase 2/3 COV002 trial. |
| 13-Oct-21 | preprint Research Square | Early treatment with inhaled GM-CSF improves<br>oxygenation and anti-viral immunity in COVID-19<br>induced lung injury – a randomized clinical trial | RCT | Belgium | Lambrecht c et al. | https://assets.researchsquare.com/files/rs-959220/v1_covered.pdf?c=1634226283 | NCT04326920 | inhalation of rhu-GM-CSF (sargramostim, Leukine®) | To evaluate the safety and efficacy rhu-GM-CSF (sargramostim, Leukine®) of 5 days of inhalation of rhu-GM-CSF (sargramostim, Leukine®) in non-ventilated patients with COVID-19 and hypoxemic respiratory failure identified by PaO2/FiO2 ratio < 350mmHg. |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 13-Oct-21 | Radiotherapy and Oncology | Whole-Lung Low-Dose Radiation Therapy (LD-RT) for Non-Intubated Oxygen-Dependent Patients with COVID-19-Related Pneumonia Receiving Dexamethasone and/or Remdesevir | RCT | USA | Hess CB et al. | Whole-Lung Low-Dose Radiation Therapy (LD-RT) for Non-Intubated Oxygen-Dependent Patients with COVID-19-Related Pneumonia Receiving Dexamethasone and/or Remdesevir - ScienceDirect | NCT04366791 | Low-dose radiotherapy | To evaluate if the addition of LD-RT to standard drug treatments leads to reduction of biomarkers of inflammation and cardiac injury in COVID-19 patients and leads to reduction of intubation. |
| 13-Oct-2021 | The Lancet Respiratory Medicine | Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan | RCT | Taiwan | Szu-Min Hsieh | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00402-1/fulltext | NCT04695652 | MVC-COV1901 vaccine | Safety, tolerability, and immunogenicity MVC-COV1901 vaccine |
| 7-Oct-2021 | NEJM | Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 | RCT | USA | Dougan et al. | https://www.nejm.org/doi/full/10.1056/NEJMoa2102685 | NCT04427501 | bamlanivimab plus etesevimab | The primary outcome was the overall clinical status of the patients, defined as Covid-19–related hospitalization or death from any cause by day 29. |
| 29-Sep-21 | NEJM | REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 | RCT III phase | USA | Weinreich D.M., et al. | https://www.nejm.org/doi/10.1056/NEJMoa2108163 | NCT04425629 | REGEN-COV (casirivimab/imdevimab) | To evaluate the efficacy and safety of REGEN-COV (casirivimab/imdevimab), at 2400-mg or 1200-mg doses, on outpatients with Covid-19 and risk factors for severe disease. End points: hospitalization or death and the time to resolution of symptoms at day 29. |
| 29-Sep-21 | NEJM | Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine | RCT III phase | International | Falsey A.R., et al. | https://www.nejm.org/doi/10.1056/NEJMoa2105290 | NCT04516746 | AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine | To evaluate the safety, efficacy and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe Covid-19 ≥15 days after the second dose in adults, including older adults, in the USA, Chile, and Peru. |
| 22-Sep-21 | Clin Infect Dis. | Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo controlled, phase 2b tria | vaccine II phase | China | Zhu F., et al | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab845/6374123 | NCT04566770 | to assess safety and immunogenicity of a recombinant adenovirus type-5 (Ad5)-vectored COVID-19 vaccine with homologous prime-boost regimens in healthy participants aged 6 years and above. 3 doses (low-dose vaccine, middle-dose vaccine or placebo) given intramuscularly 56 days apart. | to assess safety and immunogenicity of a recombinant adenovirus type-5 (Ad5)-vectored COVID-19 vaccine with homologous prime-boost regimens in healthy participants aged 6 years and above. - 3 doses (low-dose vaccine, middle-dose vaccine or placebo) given intramuscularly 56 days apart. |
| 22-Sep-21 | NEJM | Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase | RCT III phase | USA | Sahly H.M., et al | https://www.nejm.org/doi/10.1056/NEJMoa2113017 | NCT04470427 | mRNA-1273 SARS-CoV-2 Vaccine | To evaluate the efficacy and safety data from the blinded phase of the phase 3 trial of mRNA-1273 Moderna vaccine are reported. |
| 15-Sep-21 | NEJM | SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 | RCT 1-2-3 pivotal phase | USA | Falsey A.R., et al | https://www.nejm.org/doi/10.1056/NEJMc2113468 | NCT04368728 | BNT162b2 Vaccine Dose 3 | To evaluate the safety and immunogenicity of a booster dose of BNT162b2 administered 7-9 months after the primary two-dose series |
| 15-Sep-21 | Clin Infect Dis. | Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19 | RCT | USA | Ananworanich J., et al. | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab813/6370549 | NCT04504032 | rivaroxaban | To investigate whether rivaroxaban, a direct oral anticoagulant factor Xa inhibitor would reduce COVID-19 progression. |
| 19-Sep-21 | Clin Infect Dis. | Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile | RCT III phase | Chile | Bueno S.M., et al. | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab823/6372423 | NCT04651790 | Inactivated SARS-CoV-2 Vaccine | To evaluate the safety and immunogenicity of inactivated SARS-CoV-2 vaccine CoronaVac |
| October-2021 | Pharm Res & Prosp | Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8 | RCT | Germany & USA | Port et al. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377444/ | NCT03676322 | enpatoran | Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of enpatoran |
| October-2021 | International Immunopharmacology | Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials | metaanalysis of RCT | Taiwan | Chen et al. | https://pubmed.ncbi.nlm.nih.gov/34343937/ | NA | JAK inhibitors (baricritinib, tofacitinib, ruxolitinib) | Clinical efficacy and safety of Janus kinase (JAK) inhibitors for COVID-19 patients |
| October-2021 | International Immunopharmacology | An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial | RCT | Iran | Darazam et al. | https://pubmed.ncbi.nlm.nih.gov/34224994/ | NCT04521400 | IFN-β 1a | The effectiveness of high-dose IFN-β 1a compared to low dose IFN-β 1a in severe COVID-19 cases. |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 10-Aug-21 | Lancet | Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial | RCT | UK | Yu L.M., et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01744-X/fulltext | ISRCTN86534580 | Inhaled budesonide | To establish whether inhaled budesonide reduces time to recovery and COVID-19-related hospital admissions or deaths among people at high risk of complications in the community. |
| 11-Aug-21 | NEJM | Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients | RCT | Canada | Hall V.G., et al. | https://www.nejm.org/doi/10.1056/NEJMc2111462 | NCT04885907. opens in new tab | mRNA-1273 Vaccine | Double-blind, randomized, controlled trial of a third dose of mRNA 1273 vaccine (Moderna) as compared with placebo in transplant recipients. |
| 11-Aug-21 | NEJM | Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents | RCT | USA | Ali K., et al. | https://www.nejm.org/doi/10.1056/NEJMoa2109522 | NCT04649151 | mRNA-1273 vaccine | To test safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in adolescents. |
| 18-Aug-21 | NEJM | Early Convalescent Plasma for High-Risk Outpatients with Covid-19 | RCT | USA | Korley F.K., et al | Early Convalescent Plasma for High-Risk Outpatients with Covid-19 \| NEJM | NCT04355767. opens in new tab. | Convalescent plasma | Randomized, multicenter, single-blind trial, on COVID-19 patients treated in emergency departments receiving either one unit of convalescent plasma with a high titer of antibodies against SARS CoV-2 or placeb |
| 19-Aug-21 | Blood Advances | Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma | RCT | Israel | Perry C., et al | Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma \| Blood Advances \| American Society of Hematology (ashpublications.org) | NCT04746092 | SARS-CoV-2 vaccine | To investigate the humoral response to SARS-CoV-2 vaccine in patients with B-NHL and looked at factors affecting the response rate to the vaccine |
| 23-Aug-21 | Clin Microbiol Infect | Immunogenicity and safety of the BNT162b2 mRNA Covid-19 vaccine in people living with HIV-1 | RCT | Israel | Levy I., et al | https://linkinghub.elsevier.com/retrieve/pii/S1198743X21004237 | NA | Pfizer-BioNTech BNT162b2 mRNA | To assess the immunogenicity and safety the Pfizer-BioNTech BNT162b2 mRNA vaccine in people living with HIV-1 (PLWH) . |
| 1-Sep-21 | Clin Infect Dis | Fostamatinib for the treatment of hospitalized adults with COVD-19 A randomized trial | RCT | USA | Strich J.R., et al | Fostamatinib for the treatment of hospitalized adults with COVID-19 A randomized trial \| Clinical Infectious Diseases \| Oxford Academic (oup.com) | NCT04579393 | Fostamatinib | To evaluate if Fostamatinib will ameliorate Fc activation and attenuate harmful effects of the anti-COVID-19 immune response. |
| 1-Sep-21 | Lancet | Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) | RCT | USA | Flaxman A., et al. | Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) - The Lancet | NCT04324606, NCT04400838 | ChAdOx1 nCoV-19 | To assess the persistence of immunogenicity after a single dose of ChAdOx1 nCoV-19 (AZD1222), immunity after an extended interval (44–45 weeks) between the first and second dose, and response to a third dose as a booster given 28–38 weeks after the second dose. |
| 1-Sep-21 | Lancet Respir Med | Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo controlled phase 3 trial | RCT | USA | Marconi V. C., et | Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial - The Lancet Respiratory Medicine | NCT04421027 | Baricitinib | To evaluate the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults with COVID-19. |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 3-Sep-21 | Nature Med. | Early treatment of COVID 19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double blind, randomized controlled phase 3 trial | RCT | Greece | Kyriazopoulou, E., | Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial \| Nature Medicine | NCT04680949 | Anakinra | To evaluate if and early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure |
| 7-Sep-21 | Lancet Rheumatol. | Humoral and cellular responses to mRNA vaccines against SARS CoV-2 in patients with a history of CD20 B-cell depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study | RCT | Switzerland | Moor M.B., et al. | Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study - The Lancet Rheumatology | NCT04877496. | SARS-CoV-2 mRNA | To investigate humoral and cell-mediated immune responses to SARS-CoV-2 mRNA-based vaccines in patients receiving CD20-targeted B-cell-depleting agents (rituximab or ocrelizumab). |
| 14-Sep-21 | Lancet Infect Dis | Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial | RCT | France | Ader F., et al | https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00485-0/fulltext | NCT04315948 | Remdesivir | To evaluate the clinical efficacy of remdesivir plus standard of care (SoC) compared with SoC alone in patients admitted to hospital with COVID-19, with indication of oxygen or ventilator support. |
| 15-Sep-21 | Nature Med. | Safety and immunogenicity of SARS CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis | RCT | USA | Choi A., et al. | https://www.nature.com/articles/s41591-021-01527-y | NCT04405076) | single booster dose of mRNA-1273 or variant-modified mRNAs, including multivalent mRNA-1273.211. | exploratory interim analysis to evaluate the primary objectives of safety and immunogenicity of a single booster dose of mRNA-1273 or variant-modified mRNAs, including multivalent mRNA-1273.211. Participants: received a two-dose primary series of the COVID-19 vaccine mRNA-1273 approximately 6 months earlier. Analysis includes preliminary descriptive results only of four booster groups (n = 20 per group). |
| 15-Sep-21 | NEJM | Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months | RCT | USA | Thomas S.J. et al. | https://www.nejm.org/doi/10.1056/NEJMoa2110345 | NCT04368728 | BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. | Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months |
| 31-Jul-21 | Medrxiv | Phase 1 Safety and Pharmacokinetics Studies of BRII-196 and BRII-198, SARS-CoV-2 Spike-Targeting Monoclonal Antibodies | Phase 1 RCT | China | Zhang et al. | https://www.medrxiv.org/content/10.1101/2021.07.21.21260964v2 | NCT04479631, NCT04479644 | BRII-196 and BRII-198 anti SARS-CoV-2 spike monoclonal antibodies | Safety, tolerability, pharmacokinetics, and immunogenicity of BRII-196 and BRII-198 |
| 8-Aug-21 | Medrxiv | Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial | RCT | Taiwan | Szu-Min et al. | https://www.medrxiv.org/content/10.1101/2021.08.05.21261532v1 | NCT04695652 | MVC-COV1901 vaccine | safety and immunogenicity of the COVID-19 vaccine MVC-COV1901 |
| 28-Jul-21 | Medrxiv | Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy | RCT | Netherlands | Rozeen et al. | https://www.medrxiv.org/content/10.1101/2021.07.27.21261116v1 | Trial NL9275 | mRNA-1273 vaccine | Tolerability and safety of mRNA-1273 vaccine |
| 14-Jul-21 | NEJM | Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 | RCT Phase 3 | USA | Dougan M., et a | https://www.nejm.org/doi/10.1056/NEJMoa2102685 | NCT04427501 | Bamlanivimab plus Etesevimab | Primary outcome: overall clinical status of the patients, defined as Covid-19–related hospitalization or death from any cause by day 29. |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 14-Jul-21 | NEJM | Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination | Correspondance | Netherland | Barouch D.H., et al. | https://www.nejm.org/doi/10.1056/NEJMc2108829 | NCT04436276. | Ad26.COV2.S vaccine | To describe the 8-month durability of humoral and cellular immune responses in 20 participants who received the Ad26.COV2.S vaccine in one or two doses (either 5×1010 viral particles or 1011 viral particles) and in 5 participants who received placebo. |
| 14-Jul-21 | Nature Medicine | Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination | Brief Communication | Germany | Barros-Martins J et al. | Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination \| Nature Medicine | NA | ChAd-primed and 3 weeks after booster with ChAd or BioNTech/Pfizer's BNT162b2 | To monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd or BioNTech/Pfizer's BNT162b2. |
| 12-Jul-21 | JAMA | Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women | cohort study | Israel | Goldshtein I., et al | https://jamanetwork.com/journals/jama/fullarticle/2782047 | NA | BNT162b2 mRNA vaccine | To assess the association between receipt of BNT162b2 mRNA vaccine and risk of SARS-CoV-2 infection among pregnant women. |
| 08-Jul-21 | Lancet | Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo controlled, phase 3 trial in Turkey | RCT | Turkey | Tanriover M.D., et al | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01429-X/fulltext | NCT04582344 | Inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac | Interim efficacy and safety results of a phase 3 clinical trial of CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, in Turkey |
| 30-Jun-21 | NEJM | Safety and Efficacy of NVX CoV2373 Covid-19 Vaccine | RCT | UK | Heath P.T., el al. | Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine \| NEJM | 2020-004123-16 | NVX-CoV2373 vaccine (Novavax) is a recombinant nanoparticle vaccine against SARS-CoV-2 that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvan | To assess the Safety and Efficacy of NVX CoV2373 Covid-19 Vaccine |
| 20-Jul-21 | JAMA | Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19 | RCT | International | Caricchio R. et al. | https://jamanetwork.com/journals/jama/article-abstract/2782185?resultClick=1 | NCT04362813 | canakinumab, an anti–interleukin-1β antibody | Is the anti–interleukin-1β antibody canakinumab effective to treat patients hospitalized with COVID-19 and hyperinflammation? |
| 16-Jul-21 | JAMA | Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection | RCT | USA | Oldenburg CE et al. | https://jamanetwork.com/journals/jama/fullarticle/2782166?resultClick=1 | NCT04332107 | Azithromycin | To determine whether oral azithromycin in outpatients with SARS-CoV-2 infection leads to absence of self-reported COVID-19 symptoms at day 14 |
| 6-Jul-21 | JAMA | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 | Meta-analysis | International | The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group | https://jamanetwork.com/journals/jama/fullarticle/2781880?resultClick=1 | NA | IL-6 antagonists | Is administration of IL-6 antagonists associated with 28-day all-cause mortality in patients hospitalized for COVID-19? |
| 2-Jul-21 | The Lancet Respiratory Medicine | BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers | RCT | Israel | Lustig et al. | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00220-4/fulltext | NA | Comirnaty Vaccine | Early antibody responses and antibody kinetics after each vaccine dose in health-care workers of different ages and sexes, and with different comorbidities |
| 9-Jul-21 | The Lancet Respiratory Medicine | Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial | RCT | UK | Hinks et al. | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00263-0/fulltext | NCT04381962 | azithromycin | Whether azithromycin is effective in reducing hospital admission in patients with mild-to-moderate COVID-19 |
| 2-Jul-21 | BMC Infectious Diseases | Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial | RCT | Argentina | Vallejos et al. | https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06348-5 | NCT04529525 | Ivermectin | Whether ivermectin treatment can prevent hospitalization in individuals with early COVID-19 |
| 15-Jul-21 | NEJM | Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents | RCT | USA | Frenck et al. | https://www.nejm.org/doi/10.1056/NEJMoa2107456?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed | NCT04368728 | BNT162b2 | Safety and efficacy of BNT162b2 vaccine against COVID-19 |
| 28-Jun-21 | The Lancet Infectious Diseases | Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial | RCT | China | Han et al. | https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00319-4/fulltext | NCT04551547 | CoronaVac vaccine | Assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, CoronaVac in children and adolescents aged 3–17 years |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 19-Jun-21 | International Journal of Infectious Diseases | Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomised controlled trial | Bayesian re-analysis | UK | Hamilton FW et al. | https://www.sciencedirect.com/science/article/pii/S1201971221005233?via%3Dihub | NCT04381936 | convalescent plasma | To re-analyse of the data using Bayesian methods suggests there is a real possibility of benefit of convalescent plasma |
| 16-Jun-21 | NEJM | Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia | RCT | Brazil | Guimarães P.O.,et al | Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia \| NEJM | NCT04469114 | Tofacitinib | To evaluate efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with Covid-19 pneumonia. |
| 9-Jun-21 | Nature | Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans | Re-using the samples collected from RCT | International | Alter G., et al | https://www.nature.com/articles/s41586-021-03681-2 | NCT04436276 | Ad26.COV2.S vaccine | Study of the humoral and cellular immune responses induced by Ad26.COV2.S against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1., and B.1.351 variants (Population enroled at COV1001 phase 1/2 clinical trial) |
| 12-Jun-21 | International Immunopharmacology | Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial | RCT | Iran | HosseinKasiri | Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial - ScienceDirect | IRCT20190804044429N6 | Mometasone furoate nasal spray | To evaluate the usage of mometasone furoate nasal spray in the recovery of patients with severe microsmia or anosmia induced by COVID-19. |
| 4-jun-2021 | Lancet | Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial | RCT | Brazil | Lopes et al | https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2901203-4 | NCT04394377 | rivaroxaban, enoxaparin, heparin | to compare the efficacy and safety of therapeutic versus prophylactic anticoagulation |
| 17-Jun-21 | The Lancet Respiratory Medicine | Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial | RCT | Netherlands | Aman et al. | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00237-X/fulltext | EudraCT 2020–001236–10 | imatinib | Does imatinib reduce the time to discontinuation of ventilation and supplemental oxygen in patients with COVID-19? |
| 28-Jun-21 | The Lancet Infectious Diseases | Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial | RCT | China | Han et al. | https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00319-4/fulltext | NCT04551547 | CoronaVac vaccine | To assess the safety, tolerability, and immunogenicity of COVID-19 vaccine CoronaVac in children and adolescents aged 3–17 years |
| 25-Jun-21 | The Lancet | Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial | RCT | Spain | Borobia et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01420-3/fulltext | NCT04860739, EudraCT 2021-001978-37 | Comirnaty and AstraZeneca vaccine | To assess the immunogenicity and reactogenicity of BNT162b2 (Comirnaty, BioNTech, Mainz, Germany) administered as second dose in participants primed with ChAdOx1-S (Vaxzevria, AstraZeneca, Oxford, UK). |
| 9-jun-2021 | MedRxiv | Pyridostigmine in the treatment of adults with severe SARS-CoV-2 infection (PISCO): a 2 randomised, double-blinded, phase 2/3, placebo-controlled trial | RCT | Mexico | Fragoso-Saavedra et al | https://www.medrxiv.org/content/10.1101/2021.04.28.21255834v2.full.pdf | NCT04343963 | pyridostigmine | to evaluate whether pyridostigmine could decrease invasive mechanical ventilation (IMV) and death in patients with severe COVID-19 |
| 8-jun-2021 | MedRxiv | Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized controlled trial (SEV COVID Trial) | RCT | India | Singh et al | https://www.medrxiv.org/content/10.1101/2021.06.06.21258091v1.full.pdf | The trial was registered at the Clinical Trial Registry of India (CTRI/2020/06/025575) | hydroxychloroquine, lopinavir-ritonavir, ribavirin | To evaluate the therapeutic potential of hydroxychloroquine and lopinavir-ritonavir in combination with ribavirin in COVID-19 |
| 16-jun-2022 | MedRxiv | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Running title: REGEN-COV for COVID-19 | RCT | UK | RECOVERY Group | https://www.medrxiv.org/content/10.1101/2021.06.15.21258542v1.full.pdf | NCT04381936 | REGEN-COV (casirivimab and imdevimab) | To evaluate the efficacy and safety of REGEN-COV (a combination of 2 monoclonal antibodies (casirivimab and imdevimab) that bind to two different sites on the receptor binding domain of the 26 SARS-CoV-2 spike protein) in patients admitted to hospital with COVID-19 |
| 8-jun-2021 | MedRxiv | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Running title: Aspirin for COVID-19 | RCT | UK | RECOVERY Group | https://www.medrxiv.org/content/10.1101/2021.06.08.21258132v1 | NCT04381936 | acetylsalicylic acid | To evaluate the effects of aspirin in patients hospitalised with COVID-19 |
| 27-May-2021 | NEJM | Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents | multinational, placebo-controlled, observer-blinded trial | USA | Frenck RW et al | https://www.nejm.org/doi/pdf/10.1056/NEJMoa2107456?articleTools=true | NCT04368728 | BNT162b2 or placebo | To assess the safety (reactogenicity and ad- verse events) and efficacy against confirmed Covid-19 ≥7 days after dose 2 in the 12-to-15-year-old cohort |
| 13-May-2021 | NEJM | Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | multicenter, placebo-controlled, phase 1–2a trial | The Netherlands | Sadoff J et al | https://www.nejm.org/doi/pdf/10.1056/NEJMoa2034201?articleTools=true | NCT04436276 | Ad26.COV2.S vaccine (J&J) at a dose of 5×1010 viral particles (low dose) or 1×1011 viral particles (high dose) | The safety and immunogenicity profiles of Ad26.COV2 |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 21-May-2021 | MedRxiv | Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial | single-blinded parallel-randomized controlled trial | Egypt | Elgohary MA et al | https://www.medrxiv.org/content/10.1101/2021.05.19.21257429v1.full.pdf | NCT04530422 | Sofosbuvir/ledipasvir (S.L. group) vs control group (Oseltamivir, Hydroxychloroquine, and Azithromycin (OCH group)) | To investigate the efficacy of Sofosbuvir/ledipasvir in the treatment of COVID-19 compared to the standard of care |
| 27-May-21 | Lancet Respir Med | Colchicine for community treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial | RCT | Canada | Tardif J., et al. | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00222-8/fulltext | NCT04322682 | Colchicine | To investigate the effect of colchicine (oral anti-inflammatory) on the composite of COVID-19-related death or hospital admission. |
| 26-May-21 | JAMA | Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial | RCT | United Arab Emirates and Bahrain a | Kaabi NA. et al. | https://jamanetwork.com/journals/jama/fullarticle/2780562 | NCT04510207 | inactivated SARS-CoV-2 vaccines | To evaluate the efficacy and adverse events of 2 inactivated COVID-19 vaccines |
| 27-May-21 | Nature | BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans | vaccine trial | Germany | Sahin U., et al | https://www.nature.com/articles/s41586-021-03653-6 | NCT04380701 | BNT162b2 vaccine | To extend the previous phase 1/2 trial report and present BNT162b2 prime/boost induced immune response data from a second phase 1/2 trial in healthy adults (18-55 years of age). |
| 25-May-21 | Clin Microbiol Infect | An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 (DisCoVeRy) | RCT | France | Ader F., et al | https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(21)00259-7/fulltext | NCT04315948 | lopinavir/ritonavir, lopinavir/ritonavir-IFN-ß-1a and hydroxychloroquine | To evaluate clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to standard of care (control) in COVID-19 inpatients requiring oxygen and/or ventilatory support. |
| 3-Jun-21 | JAMA | Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities A Randomized Clinical Trial | RCT | USA | Cohen M., et al. | https://jamanetwork.com/journals/jama/fullarticle/2780870 | NCT04497987 | bamlanivimab | To determine the effect of bamlanivimab on the incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities. |
| 22-May-21 | NEJM | Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia | RCT | USA | Rosas et al. | https://www.nejm.org/doi/10.1056/NEJMoa2028700 | NCT04320615 | Tocilizumab | Efficacy of tocilizumab in patients with severe COVID-19 infection |
| 26-May-21 | Viruses | Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon | RCT | Lebanon | Samaha AA. et al. | https://www.mdpi.com/1999-4915/13/6/989/htm | NA | Ivermectin | To determine the efficacy of ivermectin, an FDA-approved drug, in producing clinical benefits and decreasing the viral load of SARS-CoV-2 among asymptomatic subjects that tested positive for this virus in Lebanon |
| 5-May-2021 | NEJM | Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant | Phase 2a-b RCT | South Africa | Shinde et al (2019nCoV-501 Study Group) | https://www.nejm.org/doi/pdf/10.1056/NEJMoa2103055?articleTools=true | NCT04533399 | NVX-CoV2373 vaccine (Novavax) | To assess the efficacy of a two-dose regimen of NVX-CoV2373 nanoparticle vaccine in preventing symptomatic Covid-19 during predominant transmission of the B.1.351 variant in South Africa |
| 13-May-2021 | NEJM | Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | Phase 1–2a trial | The Netherlands | Sadoff et al | https://www.nejm.org/doi/pdf/10.1056/NEJMoa2034201?articleTools=true | NCT04436276 | Ad26.COV2.S vaccine (janssen vaccine) at a dose of 5×1010 viral particles (low dose) or 1×1011 viral particles (high dose) per milliliter or placebo in a single-dose or two-dose schedule. | Interim results of a multicenter, randomized, double-blind, placebo-controlled, phase 1–2a clin- ical trial (COV1001) involving healthy adults in two age cohorts to evaluate the safety, reactoge- nicity, and immunogenicity of Ad26.COV2.S |
| 4-May-2021 | BMC Infectious Diseases | Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients | Prospective, randomized, controlled, single-blind phase 3 study | Turkey | Okumus et al | https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/s12879-021-06104-9.pdf | NCT04646109 | Ivermectin 200 mcg/kg/day for 5 days in the form of a solution prepared for enteral use added to the reference treatment protocol: hydroxychloroquine + favipiravir + azithromycin Patients in the control group were given only reference treatment with 3 other drugs without ivermectin | To investigate the presence of gene mutations that alter ivermectin metabolism and cause toxic effects in patients with severe COVID-19 pneumonia, and to evaluate the effectiveness and safety of ivermectin use in the treatment of patients without mutation. |
| 5-May-2021 | MedRxiv | Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study. | Phase 1b/2a RCT (AGILE) | UK | Khoo et al | https://www.medrxiv.org/content/10.1101/2021.05.03.21256309v1.full.pdf | NCT04746183 | 300mg, 600mg and 800mg doses of molnupiravir orally, twice daily for 5 days or control | To determine the safety and tolerability of multiple ascending doses of molnupiravir in participants with symptomatic COVID-19 to recommend a dose for phase II. |
| 7-May-2021 | MedRxiv | Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure | Phase 2 CT | USA | Mammen P et al | https://www.medrxiv.org/content/10.1101/2021.05.07.21256652v1.full.pdf | NCT04642638 | DNA vaccine (INO-4800) | To assess the safety and immunogenicity of a DNA vaccine (INO-4800) targeting the full-length Spike antigen of SARS-CoV-2 when given to adults at high-risk of exposure |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 18-May-21 | Nature Med. | Phase 1 randomized trial of a plant-derived virus like particle vaccine for COVID-19 | RCT vaccine phase 1 | Canada | Ward B.J., et al. | https://www.nature.com/articles/s41591-021-01370-1 | NCT04450004 | CoVLP (virus-like particle) vaccine candidate produced in plants | To evaluate the short-term tolerability/safety and immunogenicity of CoVLP formulations assessed by neutralizing antibody (NAb) and cellular responses. |
| 17-May-21 | Clin Infect Dis. | The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real world data | historical cohort study | Israel | Chodick G., et al. | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab438/6276888 | NA | BNT162b2 vaccine | To evaluate the effectiveness of BNT162b2 vaccine in preventing SARS-CoV-2 infection and COVID-19-related hospitalization and mortality. |
| 14-May-21 | Lancet | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial | RCT | UK | RECOVERY Collaborative Group | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00897-7/fulltext | NCT04381936 | Convalescent plasma | To evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19 |
| 21-May-21 | Rev Invest Clin | Methylene Blue for Treatment of Hospitalized COVID-19 Patients: A Randomized, Controlled, Open-Label Clinical Trial, Phase 2 | RCT | Iran | Hamidi-Alamdari | https://www.clinicalandtranslationalinvestigation.com/files/ric_21_73_3_190-198.pdf | NCT04370288 | Methylene Blue | To evaluate the effect of the reduced form of methylene blue (MB) on the improvement of oxygen saturation (SpO2) and respiratory rate (RR). |
| 21-May-21 | MedRxiv | REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients | RCT | USA | Weinreich D, et al. | https://www.medrxiv.org/content/10.1101/2021.05.19.21257469v1 | NCT04425629 | REGEN-COV antibody cocktail (casirivimab with imdevimab) | To evaluate the risk of hospitalization or death, and time to symptom resolution. |
| 22-Apr-21 | EClinicalMedicine | Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19 a double-blind randomized controlled trial. | RCT | Denmark | Gunst et al. | https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00129-2/fulltext | NCT04321096 | camostat mesilate | Does camostat mesilate improve clinical outcomes of COVID-19 patients? |
| 16-Apr-21 | Critical Care Medicine | Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York A Double-Blind Randomized Trial | RCT | USA | Bennet-Guerrero | https://journals.lww.com/ccmjournal/Abstract/9000/Severe_Acute_Respiratory_Syndrome_Coronavirus_2.95264.aspx | NCT04344535 | Convalescent plasma | Does convalescent plasma increases antibodies and improves clinical outcomes of COVID-19 patients? |
| 13-May-21 | BMJ | Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study | Observational study | UK | Bernal et al. | https://www.bmj.com/content/373/bmj.n1088 | NA | Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccine | To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms |
| 20-Apr-2021 | JAMA | Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19 | RCT | USA | Stephenson KE et al | https://pubmed.ncbi.nlm.nih.gov/33704352/ | NCT04436276 | Ad26.COV2.S vaccine (by Janssen Pharmaceutical Companies) | To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the kinetics, magnitude, and phenotype of SARS-CoV-2 spike-specific humoral and cellular immune responses |
| 11-Mar-2021 | J of Medical Virology | Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19 | CT | Egypt | Elalfy H et al | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014583/pdf/JMV-9999-0.pdf | NCT04392427 | Combination of nitazoxanide, ribavirin, and ivermectin plus Zinc vs supportive treatment | To compare the rate and time of viral clearance in subjects receiving the combination of nitazoxanide, ribavirin, and ivermectin plus zinc versus those receiving supportive treatment. |
| 20-Apr-2021 | MedRxiv | Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti- SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study | RCT | France | Gaborit B et al | https://www.medrxiv.org/content/10.1101/2021.04.15.21255549v1.full.pdf | NCT04453384 | XAV-19 0.5 mg/kg at day 1 and day 5 (group 1), 2 mg/kg at day 1 and day 5 (group 2), 2 mg/kg at day 1 (group 3) or placebo | To assess the pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2, in COVID-19-related moderate pneumonia |
| 21-Apr-21 | NEJM | Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | Vaccine RCT III phase | International | Sadoff J et al. | https://www.nejm.org/doi/10.1056/NEJMoa2101544 | NCT04505722 | Ad26.COV2.S vaccine | To assest the Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 |
| 16-Apr-21 | Blood | Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Vaccine trial | Israel | Herishanu Y, et al. | https://ashpublications.org/blood/article/doi/10.1182/blood.2021011568/475742/Efficacy-of-the-BNT162b2-mRNA-COVID-19-Vaccine-in | NCT04746092 | BNT162b2 mRNA COVID19 vaccine | To determine the efficacy of COVID-19 vaccine in patients with CLL. |
| 28-Apr-21 | Chinese Medical Journal | Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials | vaccine RCT I/II phase | China | Pan HX, et al. | https://journals.lww.com/cmj/Abstract/9000/Immunogenicity_and_safety_of_a_SARS_CoV_2.98627.aspx | ChiCTR2000038804, ChiCTR2000039462 | KCONVAC - SARS-CoV-2 inactivated vaccine | To assess the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults. |
| 22-Apr-21 | *JAMA Netw Open.* | Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19 The TOGETHER Randomized Clinical Trial | RCT | International | Reis G et al. | https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779044 | NCT04403100 | hydroxychloroquine or lopinavir-ritonavir | To determine whether hydroxychloroquine or lopinavir-ritonavir reduces hospitalization among high-risk patients with early symptomatic COVID-19 in an outpatient setting. |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 5-May-21 | MedRxiv | Pyridostigmine in adults with severe SARS-CoV 2 infection: the PISCO trial | RCT | Mexico | Fragoso-Saavedra S, et al. | https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/ppmedrxiv-21255834 | NCT04343963 | pyridostigmine | to evaluate whether pyridostigmine could decrease invasive mechanical ventilation (IMV) and death in patients with severe COVID-19 |
| 5-May-21 | The Lancet | Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data | Observational study | Israel | Haas et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00947-8/fulltext | NA | BNT162b2 | Real-world effectiveness of two doses of BNT162b2 against SARS-CoV-2 |
| 1-May-21 | The Lancet | Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial | RCT | UK | Horby et al. (RECOVERY Collaborative Group) | https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900676-0 | NCT04381936 | Tocilizumab | What is the effect of tocilizumab in adult patients admitted to hospital with COVID-19 |
| 27-Apr-21 | The Lancet Oncology | Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study | Observational study | UK | Manin et al. | https://www.thelancet.com/action/showPdf?pii=S1470-2045%2821%2900213-8 | NA | BN162b2 vaccine | To assess the safety and immunogenicity of the BNT162b2 (Pfizer–BioNTech) vaccine in patients with cancer |
| 9-Apr-21 | Lancet Respir Med. | Inhaled budesonide in the treatment of early COVID 19 (STOIC): a phase 2, open-label, randomised controlled trial | RCT 2 phase | UK | Ramakrishnan S., et al. | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00160-0/fulltext | NCT04416399 | inhaled glucocorticoid budesonide | To evaluate the efficacy of the widely used inhaled glucocorticoid budesonide in individuals with early COVID-19 in the community. |
| 30-Mar-21 | Lancet | Efficacy of ChAdOx1 nCoV19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial | vaccine | UK | Emary K.R.W., et al | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00628-0/fulltext | NCT04400838 | ChAdOx1 nCoV 19 (AZD1222) vaccine | post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against the variant B.1.1.7. |
| 10-Apr-21 | BMC Infectious Diseases | Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial | RCT | Iran | Ranjbar B | https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06045-3 | IRCT20200204046369N1 | Methylprednisolone or dexamethason | To assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients. |
| 8-Apr-2021 | MedRxiv | Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials | Two phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials of KCONVAC | China | Pan H et al | https://www.medrxiv.org/content/10.1101/2021.04.07.21253850v1.full.pdf | NCT04758273 AND NCT04756323 | KCONVAC | To report the immunogenicity and safety of a SARS-CoV-2 inactivated vaccine, KCONVAC, in healthy adults. |
| 1-Apr-2021 | MedRxiv | INTERIM REPORT: SAFETY AND IMMUNOGENICITY OF AN INACTIVATED VACCINE AGAINST SARS-COV-2 IN HEALTHY CHILEAN ADULTS IN A PHASE 3 CLINICAL TRIAL | Interim analysis of a multicenter phase 3 CT | Chile | Bueno SM et al | https://www.medrxiv.org/content/10.1101/2021.03.31.21254494v1.full.pdf | NCT04651790 | CoronaVac | To evaluate safety parameters and immunogenicity against SARS-CoV-2 after immunization with CoronaVac |
| 30-Mar-2021 | MedRxiv | A RANDOMIZED TRIAL - INTENSIVE TREATMENT BASED IN IVERMECTIN AND IOTA-CARRAGEENAN AS PRE-EXPOSURE PROPHYLAXIS FOR COVID- 19 IN HEALTHCARE AGENTS | RCT | Argentina | Chahla RE et al | https://www.medrxiv.org/content/10.1101/2021.03.26.21254398v1.full.pdf | NCT04701710 | Ivermectin / IotaCarrageenan | To assess the effect of oral Ivermectin treatment, which has been associated with iota-carrageenan in repeated doses through the nasal and oral topical route, on the appearance and eventual progression of COVID-19 disease in a healthy population that are exposed to it and have a higher risk of contagion of SARS-COV-2 |
| 15-Apr-2021 | MedRxiv | Efficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID- 19 in hospital personnel dedicated to patients care with COVID-19 disease | RCT (CARR-COV-02) | Argentina | CARR-COV2 Trial Group collaborators | https://www.medrxiv.org/content/10.1101/2021.04.13.21255409v1.full.pdf | NCT04521322 | Nasal spray containing Iota-Carrageenan (I-C) or placebo for 21 days. | To assess the use of a nasal spray containing I-C in the prophylaxis of COVID-19 in hospital personnel dedicated to care of COVID-19 patients |
| 15-Apr-2021 | MedRxiv | Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report | preliminary report | Brazil | De Faria E et al | https://www.medrxiv.org/content/10.1101/2021.04.12.21255308v1.full.pdf | NA | CoronaVac | to report the occurrence of symptomatic COVID-19 in a cohort of healthcare workers (HCW) vaccinated with CoronaVac and to estimate its effectiveness. |
| 8-Apr-2021 | EClinicalMedicine | RBD-specific polyclonal F(abl)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial | phase 2/3, double-blind, placebo-controlled, multicenter clinical | Argentina | Lopardo et al | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037439/pdf/main.pdf | NCT04494984 | Equine poly- clonal antibodies (EpAbs) | To analyze the safety and efficacy of specific anti SARS-COV-2 EpAbs in hospitalized patients with moderate and severe COVID-19 disease |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 12-Apr-2021 | Int J of Infectious Diseases | Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: a randomized clinical trial | double-blind, single-center study | Iran | Siami Z et al | https://pubmed.ncbi.nlm.nih.gov/33878462/ | NA | Diphenhydramine Compound (Diphenhydramine + Ammonium Chloride) plus standard of care or Diphenhydramine alone and standard of care groups | Quaternary ammonium compounds have been demonstrated to have antiviral effects and may be of use against SARS-CoV-2 infections. |
| 13-Apr-2021 | Scientific reports | Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial | three-armed, individually-randomized, open-label, controlled trial | Iran | Darazam IA et al | https://www.nature.com/articles/s41598-021-86859-y | NCT04343768 | IFNβ1a and IFNβ1b | To determine any possible effects and safety concerns of the two most promising exogenously administrable IFNs on the course and outcomes of patients hospitalized with severe COVID-19. |
| 30-Mar-2021 | Nature Comm | Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial | randomized, single-blind, placebo-controlled trial | USA | Jagannathan P et al | https://pubmed.ncbi.nlm.nih.gov/33785743/ | NCT04331899 | 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) | To evaluate the efficacy of Lambda in reducing the duration of viral shedding in outpatients. |
| 24-Mar-21 | The Lancet Infectious Diseases | Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials | RCT - vaccine - phase I/II | China | ShilongYang, et al. | https://www.sciencedirect.com/science/article/S1473309921001274/pii/?via%3Dihub | NCT04445194 and NCT04466085 | ZF2001 Vaccine - protein subunit vaccine against COVID-19 using a dimeric form of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein as the antigen | To assess the safety and immunogenicity of this vaccine, ZF2001, and determine the appropriate dose and schedule for an efficacy study. |
| 25-Mar-21 | Therapeutic Advances in Respiratory Disease | Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis | meta-analysis | Mexico | Zuñiga RAA, et al. | https://journals.sagepub.com/doi/10.1177/17534666211007214 | NA | remdesivir, chloroquine, hydroxychloroquine, lopinavir, ritonavir, dexamethasone, and convalescent plasma, | To assess the clinical effectiveness of drugs used in hospitalized patients with COVID-19 infection. |
| 25-Mar-21 | JAMA | Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure The HENIVOT Randomized Clinical Trial | RCT | International | Domenico Luca Grieco | https://jamanetwork.com/journals/jama/fullarticle/2778088 | NCT04502576 | oxygen | To assess whether helmet noninvasive ventilation can increase the days free of respiratory support in patients with COVID-19 compared with high-flow nasal oxygen alone. |
| 18-Mar-21 | JAMA | Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit The INSPIRATION Randomized Clinical Trial | RCT | Iran | INSPIRATION Investigators | https://jamanetwork.com/journals/jama/fullarticle/2777829 | NCT04486508 | enoxaparin, 1 mg/kg daily vs standard prophylactic anticoagulation enoxaparin, 40 mg daily | To evaluate the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU) |
| 8-Mar-2021 | Lancet Infect Dis | Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial | Vaccine trial Phase II | India | Ella R., et al. | https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00070-0/fulltext | NCT04471519 | BBV152 (Bharat Biotech) vaccine | To evaluate the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152. |
| 4-Mar-2021 | JAMA | Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19A Randomized Clinical Trial | RCT Phase III | Colombia/USA | Lopez-Medina E., et al. | https://jamanetwork.com/journals/jama/fullarticle/2777389 | NCT04405843 | Ivermectin | To determine whether ivermectin is an efficacious treatment for mild COVID-19. |
| 4-Mar-2021 | Lancet Respir Med | Sarilumab in patients admitted to hospital with severe or critical COVID 19: a randomised, double blind, placebo-controlled, phase 3 trial | RCT Phase III | International | Lescure FX., et al. | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00099-0/fulltext | NCT04327388 | Sarilumab | To assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19. |
| 4-Mar-2021 | Lancet | Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial | RCT Phase III | UK | PRINCIPLE Trial Collaborative Group | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00461-X/fulltext | ISRCTN86534580 | Azithromycin | To assess the effectiveness of azithromycin to treat suspected COVID-19 among people in the community who had an increased risk of complications. |
| 1-Mar-2021 | Antimicrob Agents Chemother | Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV 2 | RCT Phase I | USA | Painter W. P., et al. | https://aac.asm.org/content/early/2021/02/24/AAC.02428-20 | NCT04392219 | Molnupiravir, EIDD-2801/MK-4482, prodrug of the active antiviral ribonucleoside analog 14ß-d-N4-hydroxycytidine (NHC; EIDD-1931) | Single and multiple doses of molnupiravir were evaluated in this first-in-human, phase 1, randomized, double-blind, placebocontrolled study in healthy volunteers, which included evaluation of the effect of food on pharmacokinetics. |
| 11-Mar-2021 | JAMA | Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19 | Vaccine trial Phase I | USA | Kathryn E. Stephenson | Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19 \| Vaccination \| JAMA \| JAMA Network | NCT04436276 | Ad26.COV2.S Vaccine (Janssen) | To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the kinetics, magnitude, and phenotype of SARS-CoV-2 spike-specific humoral and cellular immune responses. |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 10-Feb-2021 | Signal Transduct Target Ther | Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial | Vaccine trial Phase I/II | China | Shi et el. | https://pubmed.ncbi.nlm.nih.gov/33568628/ | NCT04288102 | Human umbilical cord-derived mesenchymal stem cells | To assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UC-MSCs) to treat severe COVID-19 patients with lung damage, based on our phase 1 data. |
| 9-Feb-2021 | Vaccine | A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine | RCT phase II | US | LaurenceChu | A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine - ScienceDirect | NCT04405076 | mRNA-1273 vaccine | To evaluate the safety and immunogenicity of vaccine candidate mRNA-1273, encoding the prefusion-stabilized spike protein of SARS-CoV-2. |
| 03-Mar-21 | Plos Med | Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial | RCT | Chile | Balcells MA et al | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929568/pdf/pmed.1003415.pdf | NCT04375098 | Convalescent Plasma | To evaluate the efficacy and safety of early Convalescent Plasma therapy in COVID-19 progression |
| 07-Mar-21 | Thrombosis and Haemostasis | Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial | RCT | Mexico | Gonzalez Ochoa AJ et al | https://pubmed.ncbi.nlm.nih.gov/33677827/ | ISRCTN59048638 | Oral dose of sulodexide (500 LRU twice a day) or placebo for 21 days | To evaluate the effect of sulodexide when used in the early clinical stages of COVID-19 |
| 16-Mar-21 | NEJM | Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | RCT | South Africa | Madhi SA et al | https://www.nejm.org/doi/pdf/10.1056/NEJMoa2102214?articleTools=true | NCT04444674 | ChAdOx1 nCoV-19 vaccine (AZD1222) | To assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) in people not infected with the human immunodeficiency virus (HIV) in South Africa. |
| 24-Feb-21 | NEJM | BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting | Vaccine | Israel | Dagan N., et al. | https://www.nejm.org/doi/10.1056/NEJMoa2101765 | NA | BNT162b2 mRNA Covid-19 Vaccine | Evaluation of the effectiveness of the BNT162b2 mRNA vaccine based on data from Israel's largest health care organization. |
| 19-Feb-21 | Lancet | Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV19 (AZD1222) vaccine: a pooled analysis of four randomised trials | Vaccine | UK | Voysey M., et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/fulltext | NA | ChAdOx1 nCoV-19 vaccine | Exploratory analyses of the impact on immunogenicity and efficacy of extending the interval between priming and booster doses.<br>- Immunogenicity and protection afforded by the first dose, before a booster dose has been offered. |
| 18-Feb-21 | Lancet | Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients | Vaccine | Israel | Amit S., et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00448-7/fulltext | NA | BNT162b2 vaccine | To examine early reductions in SARS-CoV-2 infection and COVID19 rates in vaccinated HCWs. |
| 28-Feb-21 | JAMA | Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19 A Systematic Review and Meta-analysis | Metaanalysis | International | Janiaud et al. | https://jamanetwork.com/journals/jama/fullarticle/2777060 | NA | convalescent plasma | Is treatment with convalescent plasma associated with improved clinical outcomes? |
| 17-Feb-21 | JAMA | Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19. A Randomized Clinical Trial | RCT | Brazil | Murai et al. | Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial \| Complementary and Alternative Medicine \| JAMA \| JAMA Network | NCT04449718 | Vitamin D3 | To investigate the effect of a single high dose of vitamin D3 on hospital length of stay in patients with COVID-19. |
| 12-Feb-21 | JAMA | Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection The COVID A to Z Randomized Clinical Trial | RCT | US | Thomas et al. | https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2776305 | NCT04342728 | Zinc gluconate (50 mg), ascorbic acid (8000 mg), both agents, or standard of care. | To examine whether high-dose zinc and/or high-dose ascorbic acid reduce the severity or duration of symptoms compared with usual care among ambulatory patients with SARS-CoV-2 infection. |
| 4-Feb-21 | JAMA | Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19. A Randomized Clinical Trial | RCT | France | Guenezan | https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2775984 | NCT04371965 | Povidone iodine (PI) solutions. | Whether nasopharyngeal application of PI could reduce the viral load of patients with nonsevere coronavirus disease 2019 (COVID-19) symptoms. |
| 22-Jan-21 | Respiration | Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial | RCT | China | Tang et al. | https://pubmed.ncbi.nlm.nih.gov/33486496/ | NCT04273321 | methylprednisolone | Efficacy and safety of corticosteroid given to the hospitalized patients with COVID-19 |
| Jan-21 | European Respiratory Journal | Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial | RCT | Brazil | Rocco et al. | https://erj.ersjournals.com/content/erj/early/2021/01/04/13993003.03725-2020.full.pdf | NCT04552483 | nitazoxanide | Efficacy and safety of nitrazoxanide in COVID-19 patients |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| Jan-21 | Stem Cell Transplantation Medicine | Umbilical cord mesenchymal stem cells for COVID-19 acuterespiratory distress syndrome: A double-blind, phase 1/2a,randomized controlled trial | RCT | USA | Lanzoni et al. | https://stemcellsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/sctm.20-0472 | NCT04355728 | mesenchymal stem cell | Safety of MSC in COVID-19 patients |
| 1-Mar-21 | MedRxiv | Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults | RCT | USA | Neil Formica et al | https://www.medrxiv.org/content/10.1101/2021.02.26.21252482v1.full.pdf | NCT04368988 | NVX-CoV2373 vaccine | Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 |
| 25-Jan-21 | Archives of Virology | Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study | RCT | Egypt | Dabbous HM et al | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829645/pdf/705_2021_Article_4956.pdf | NCT04351295 | chloroquine and favipiravir | To evaluate the efficacy of favipiravir |
| 25-Feb-21 | NEJM | Dexamethasone in Hospitalized Patients with Covid-19 | RCT | UK | Horby P et al (RECOVERY Group) | https://www.nejm.org/doi/pdf/10.1056/NEJMoa2021436?articleTools=true | NCT04381936; ISRCTN number, 50189673 | dexamethasone | To evaluate the effects of potential treatments in patients hospitalized with Covid-19 at |
| 25-Feb-21 | NEJM | Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia | RCT | USA | Rosas IO et al | https://www.nejm.org/doi/pdf/10.1056/NEJMoa2028700?articleTools=true | NCT04320615 | tocilizumab | To assess the efficacy and safety of tocilizumab in hospitalized patients with severe Covid-19 pneumonia |
| 25-Feb-21 | NEJM | Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 | RCT | UK | Gordon AC et al | https://www.nejm.org/doi/pdf/10.1056/NEJMoa2100433?articleTools=true | REMAP-CAP ClinicalTrials.gov number, NCT02735707 | tocilizumab and sarilumab | To assess the efficacy of interleukin-6 receptor antagonists in critically ill patients with Covid-19 |
| 20-Jan-21 | BMJ | Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled tria | RCT | Brazil | Veiga, V.C. et al. | https://www.bmj.com/content/372/bmj.n84 | NCT04403685 | tocilizumab | Does tocilizumab improves clinical outcomes for patients with severe or COVID-19?. |
| 13-Jan-21 | NEJM | Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | vaccine Phase I/IIa | USA | Sadoff J., et al. | Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine \| NEJM | NCT04436276. opens in new tab. | Ad26.COV2.S vaccine | The safety and immunogenicity profiles of Ad26.COV2 |
| 13-Jan-21 | NEJM | Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients | expanded access program | USA | Joyner et al. | https://www.medrxiv.org/content/10.1101/2020.05.12.20099879v1.full.pdf | NCT04338360 | Convalescent plasma | To assess whether convalescent plasma with high antibody levels rather than low antibody levels is associated with a lower risk of death.<br>Primary outcome: death within 30 days after plasma transfusion. |
| 11-Nov-20 | Postgraduate Medical Journal | Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study) | RCT | India | Rastogi et al. | https://pmj.bmj.com/content/early/2020/11/12/postgradmedj-2020-139065 | NCT04459247 | Vitamin D | Do high doses of cholecalciferol lead to SARS-CoV-2 negativity in greater proportions? |
| 29-Jan-21 | The Lancet | Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial | Phase I vaccine trial | Multinational | Richmond et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00241-5/fulltext | NCT04405908 | S-Trimer (SCB-2019) | Dose-finding and adjuvant justification of SCB-2019 vaccine |
| 02-Feb-21 | The Lancet | Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia | Phase III vaccine trial | Russia | Logunov et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext | NCT04530396 | Gam-COVID-Vac (Sputnik V) | Efficacy and safety of Gam-COVID-Vac |
| 06-Jan-21 | NEJM | Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults | RCT | Argentina | Libster R, et al. | Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults \| NEJM | NCT04479163 | Convalescent plasma | Does convalescent plasma reduce the development of severe respiratory disease? |
| 30-Dec-21 | NEJM | Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine | Vaccine - phase III | USA | Baden LR, et al. | https://www.nejm.org/doi/full/10.1056/NEJMoa2035389?query=featured_coronavirus | NCT04470427 | mRNA-1273 SARS-CoV-2 Vaccine | Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 |
| 12-Jan-21 | MedRxiv | Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial | RCT | Multinational | Holubovska et al. | https://www.medrxiv.org/content/10.1101/2021.01.05.21249237v1.full-text | NCT04682873 | enisamium | Efficacy and safety of enisamium at COVID-19 patients |
| 20-Jan-21 | MedRxiv | Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study | Vaccine trial phase I/II | Multinational | Goepfert et al. | https://www.medrxiv.org/content/10.1101/2021.01.19.20248611v1 | NCT04537208 | CoV2 preS dTM vaccine | Safety and imunogenicity of CoV2 preS dTM vaccine |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 09-Jan-21 | Annals of Intensive Care | Pilot trial of high-dose vitamin C in critically ill COVID-19 patients | RCT | China | Zhang et al. | https://link.springer.com/article/10.1186/s13613-020-00792-3 | NCT04264533 | Vitamin C | Effect of high doses of vitamin C |
| 01-Feb-21 | International Journal of Infectious Diseases | Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial | RCT | India | Udwadia et al. | https://www.sciencedirect.com/science/article/pii/S120197122032453X?via%3Dihub | CTRI/2020/05/025114 | favipiravir | Efficacy and safety of favipiravir in adults with mild-to-moderate COVID-19 |
| 08-Dec-20 | Lancet | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK | phase I/II/III vaccine trial | Multinational | Voysey et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext | ISRCTN89951424, NCT04324606, NCT04400838, and NCT04444674 | ChAdOx1 nCoV-19 vaccine | To test the safety and efficacy of the ChAdOx1 nCoV-19 vaccine |
| 11-Dec-20 | NEJM | Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 | RCT | USA | Kalil A.C., et al | Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 \| NEJM | NCT04401579 | Baricitinib plus Remdesivir | Effect of baricitinib (≤14 days) plus remdesivir (≤10 days) vs. remdesivir alone in hospitalized adults with Covid-19 |
| 17-Dec-20 | NEJM | Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia | RCT | USA | Salama et al. | https://www.nejm.org/doi/10.1056/NEJMoa2030340 | NCT04372186 | tocilizumab | To test the safety and efficacy of tocilizumab in hospitalized patients with Covid-19 pneumonia |
| 31-Dec-20 | Preprint | Exogenous Surfactant Versus Placebo in the Treatment of Moderate and Severe ARDS in COVID19: The Pilot Study of a Clinical Trial | RCT | Iran | Ghahremani et al. | https://assets.researchsquare.com/files/rs-136365/v1/adcad24b-f7ed-477b-a235-235f84f8ce1b.pdf | IRCT20091201002804N12 | surfactant | Is surfactant effective in COVID-19 paients? |
| 02-Dec-20 | NEJM | Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results | RCT | Multinational | WHO Soidarity Trial Consortium | Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results \| NEJM | NCT04315948 | remdesivir, hydroxychloroquine (HCQ), lopinavir, and interferon beta-1a (IFN) | WHO mortality trial of four repurposed antiviral drugs — remdesivir, hydroxychloroquine (HCQ), lopinavir, and interferon beta-1a (IFN)— in patients hospitalized with Covid-19. |
| 03-Dec-20 | NEJM | Durability of Responses after SARS-CoV-2 mRNA1273 Vaccination | Phase I vaccine trial | USA | Widge A.T., et al. | Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination \| NEJM | NCT04283461 | mRNA 1273 vaccine | mRNA 1273 vaccine immunogenicity 3 months after second vaccination |
| 24-Dec-20 | EClinicalMedicine | Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial | Phase I vaccine trial | USA/UK | Tebas et al. | https://www.sciencedirect.com/science/article/pii/S2589537020304338 | NCT04336410 | INO-4800 DNA vaccine | Safety and immunogenicity of INO-4800 vaccine |
| 17-Dec-20 | Nature Med. | Phase 1/2 trial of SARSCoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | Phase I/II vaccine trial | UK | Barrett J.R., et al. | https://www.nature.com/articles/s41591-020-01179-4 | NCT04400838 | ChAdOx1 nCoV-19 vaccine AZD1222 | Safety and exploratory humoral and cellular immunogenicity of the AZD1222 vaccine |
| 17-Dec-20 | NEJM | REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | RCT | USA | Weinreich D.M | REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 \| NEJM | NCT04425629 | REGN-COV2 antibody cocktail | Interim study results: effects of high viral loads with complications and death from coronavirus disease 2019 (Covid-19)-REGN-COV2 effects on outpatients |
| 22-Dec-20 | preprint - BMJ | Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report | Phase I/II vaccine trial | India | Raches et al. | https://www.medrxiv.org/content/10.1101/2020.12.21.20248643v1 | NCT04471519 | inactivated SARS-CoV-2 vaccine, BBV152 | To test the immunogenicity and safety of BBV152: 3 µg and 6 µg with Algel-IMDG. |
| 22-Dec-20 | NEJM | A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 | RCT | Denmark | ACTIV-3/TICO LY-CoV555 Study Group | A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 \| NEJM | NCT04501978 | LY-CoV555 | To test the effect of this antibody in patients who are hospitalized with Covid-19. |
| 10-Dec-20 | NEJM | Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 | RCT | USA | Stone J.H., et al | Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 \| NEJM | NCT04356937 | tocilizumab | To test the effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection. |
| 14-Dec-20 | BMC Infect Dis | Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. | RCT | Iran | Marzieh et al. | https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05698-w | IRCT20180725040596N2 | Arbidol (Umifenovir) | To determine the effect of Arbidol (ARB) on COVID-19 disease. |
| 23-Dec-20 | Trials | Interferon ß-1a (IFNß-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial. | RCT | Italy | Bosi et al. | https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04864-4 | EudraCT 2020-002458-25, NCT04449380 | Interferon ß-1a (IFNß-1a) | To test the efficacy of Interferon-β-1a (IFNβ-1a), in COVID-19 patients in an open label, randomized clinical trial. |
| 10-Dec-20 | NEJM | Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | phase II vaccine trial | USA | Polack F.P., et al. | Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine \| NEJM | NCT04368728. opens in new tab | BNT162b2 vaccine | To evaluate the efficacy and safety of BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membraneanchored SARS-CoV-2 fulllength spike protein. |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 18-Dec-20 | Journal of Antimicrobial Chemotherapy | Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial | RCT | Iran | Roozbeh et al. | https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa501/6041772?login=true | IRCT20200403046926N1 | sofosbuvir, daclatasvir | Is sofosbuvir/daclatasvir effective in COVID-19 patiets? |
| 16 November 2020 | Critical Care Explorations | Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019 | RCT | USA | George Sakoulas, et al. | https://journals.lww.com/ccejournal/Fulltext/2020/11000/Intravenous_Immunoglobulin_Plus_Methylprednisolone.14.aspx | NCT04411667 | Immunoglobulins | To asses the efficacy and safety of IV immunoglobulin in hospitalized COVID-19 patients. |
| 23 November 2020 | Biological Trace Element Research | Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial | RCT | Egypt | Sherief Abd-Elsalam, et al. | https://link.springer.com/article/10.1007/s12011-020-02512-1 | NCT04447534 | Zinc, Hydroxychloroquine | To evaluate the effect of combining chloroquine/hydroxychloroquine and zinc in the treatment of COVID-19 patients. |
| 17-Nov | MedRxiv | Effect of Vitamin D3 Supplementation vs Placebo on Hospital Length of Stay in Patients with Severe COVID-19: A Multicenter, Double-blind, Randomized 3 Controlled Trial | RCT | Brazil | Murai et al. | https://www.medrxiv.org/content/10.1101/2020.11.16.20232397v1.full.pdf | NCT04449718 | Vitamin D3 | To determine if vitamin D3 supplementation can reduce hospital length of stay in hospitalized patients with severe COVID-19? |
| 23-Nov | MedRxiv | Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial | RCT | USA | Jagannathan et al. | https://www.medrxiv.org/content/10.1101/2020.11.18.20234161v1.full.pdf | NCT04331899 | Peginterferon Lambda-1a | To determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) could shorten the duration of viral shedding or symptoms in patients with mild to moderate COVID-19. |
| 21-Nov | MedRxiv | Prevention of severe COVID-19 in the elderly by early hightiter plasma | RCT | Argentina | Libster et al. | https://www.medrxiv.org/content/10.1101/2020.11.20.20234013v1.full.pdf | NCT04479163 | Convalescent plasma | To evaluate the efficacy of convalescent plasma with high titers of SARS-CoV2 antibody administered within 72 hours of mild symptoms to elderly patients with Covid-19 |
| 02-Dec | MedRxiv | A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19 | RCT | India | Kumar et al. | https://www.medrxiv.org/content/10.1101/2020.12.01.20239574v1.full.pdf | CTRI/2020/05/024959 | Itolizumab | To estimate the efficacy and safety of Itolizumab in the treatment of cytokine release syndrome in patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19. |
| 18-Nov | MedRxiv | 5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARSCoV-2 Positive Men | RCT | Brazil, USA | Cadegiani et al. | https://www.medrxiv.org/content/10.1101/2020.11.16.20232512v1.full.pdf | NCT04446429 | Dutasteride | To determine if 5-alpha-reductase inhibitors (5ARis) are a beneficial treatment for COVID-19 if given after SARS-CoV-2 infection |
| 11-Nov | International Immunopharmacology | Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study | RCT | Mexico | Maldonado et al. | https://reader.elsevier.com/reader/sd/pii/S1567576920336766?token=EDD4B561C8D7F700793B55AFFA9EE8F0CD28010BE3E0CADC0EF90237E4EF73330CF63D0FDA8F33F2F0AD9CA7536BD33F | COF-002495 | Pentoxifylline | To test the effect Pentoxifylline (PTX) on parameters such as LDH, lymphocyte count, days of hospitalization, mortality, and the need for intubation on patients with severe and moderate COVID-19 |
| 02-Dec-20 | NEJM | Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results | RCT | Multinational | WHO Solidarity Trial Consortium | https://www.nejm.org/doi/10.1056/NEJMoa2023184 | ISRCTN83971151, NCT04315948 | hydroxychloroquine, lopinavir/ritonavir, interferon beta1, remdesivir | effects of drugs on in-hospital mortality |
| 24-Nov-20 | NEJM | A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 | RCT | Spain | Mitjà et al. | https://www.nejm.org/doi/10.1056/NEJMoa2021801 | NCT04304053 | Hydroxychloroquine | Does postexposure prophylaxis with hydroxychloroquine prevent SARS-CoV-2 infection? |
| 24-Nov-20 | NEJM | A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia | RCT | Argentina | Simonovich et al. | https://www.nejm.org/doi/10.1056/NEJMoa2031304 | NCT04383535 | Convalescent plasma | Is treatment with convalescent plasma associated with improved clinical outcomes in COVID-19 patients? |
| 19-Nov-20 | The Lancet | Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial | phase II/III vaccine trial | UK | Ramasamy et al. | https://www.sciencedirect.com/science/article/pii/S0140673620324661?via%3Dihub | NCT04400838, ISRCTN 15281137 | ChAdOx1 vaccine | Safety and immunogenicity of ChAdOx1 vaccine in young and old adults |
| 18-Nov-20 | Lancet Infect. Dis. | Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. | I/II vaccine trial | China | Zhang et al. | https://www.sciencedirect.com/science/article/pii/S1473309920308434?via%3Dihub | NCT04352608 | CoronaVac vaccine | Safety, tolerability and immunogenicity of CoronaVac vaccine |
| 04-Nov | MedRxiv | Randomized controlled trial of convalescent plasma therapy against standard therapy in 2 patients with severe COVID-19 disease | RCT | Bahrain, Ireland | Al Qahtani et al. | https://www.medrxiv.org/content/10.1101/2020.11.02.20224303v1.full.pdf | NCT04356534 | Convalescent plasma | Pilot study designed to inform the design of a definitive phase 3 clinical trial. |
| 12/11/2020 | MedRxiv | Peginterferon-lambda for the treatment of COVID-19 in outpatients | RCT | Canada | Feld et al. | https://www.medrxiv.org/content/10.1101/2020.11.09.20228098v1.full.pdf | NCT04354259 | Peginterferon | To evaluate a single subcutaneous injection of peginterferon-lambda in outpatients with COVID-19. |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 13-Nov | International Immunopharmacology | Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial | RCT | Iran | Tabarsi et al. | https://reader.elsevier.com/reader/sd/pii/S1567576920336729?token=13C23CAB7F2F51222936F6967643ECEC50F680C6C1B600298B1211225F0DFEC4733E630469CDAF7A7C222585B41FD1EE | IRCT20151227025726N20 | Intravenous Immunoglobulin | To investigate the potential usefulness of IVIg for the management of severe cases of Covid-19. |
| 9 November 2020 (preprint) | International Journal of Infectious Diseases | Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia | RCT | Oman | Faryal Khamis, et al. | https://www.sciencedirect.com/science/article/pii/S1201971220323195?via%3Dihub | NA | Favipiravir, interferon beta-1b | To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe COVID-19 pneumonia. |
| Preprint | Clinical Infectious Diseases | Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults | Phase 2 vaccine trial | China | Yanchun Che, et al. | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1703/5962856 | NCT04412538 | Inactivated vaccine | Assess the safety and immunogenitcity of this inactiviated vaccine |
| 6 November 2020 (in press) | International Journal of Antimicrobial Agents | Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study | RCT | India | Deba Prasad Dhibar, et al. | https://www.sciencedirect.com/science/article/pii/S0924857920304350?via%3Dihub | NCT04408456 | Hydroxychloroquine | To evaluate the efficacy of PEP with HCQ for the prevention of COVID-19 in asymptomatic non-HCW individuals who were at risk for SARS-CoV-2 infection |
| Preprint | MedRxiv | Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants | Phase 1 vaccine Trial | Canada | Brian J Ward, et al. | https://www.medrxiv.org/content/10.1101/2020.11.04.20226282v1 | NCT04450004 | CoVLP vaccine | To assess the safety, tolerability, and immunogenicity of CoVLP at three dose levels unadjuvanted or adjuvanted with either CpG 1018 or AS03 in healthy adults 18 to 55 years of age. |
| 27 October 2020 | E-Clinical Medicine (Lancet) | An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19 | RCT | China | Weihui Fu, et al. | https://www.sciencedirect.com/science/article/pii/S2589537020302911?via%3Dihub | ChiCTR2000030262 | IFN-κ plus TFF2 | To evaluate the efficacy and safety in patients with moderate COVID-19 f the combination of IFN-κ plus TFF2 |
| 12-Nov-20 | The Lancet Respiratory Medicine | Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial | RCT | UK | Monk et al. | https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext | 2020-001023-14, NCT04385095 | INF-beta 1a | Efficacy and safety of inhaled nebulised interferon beta-1a |
| 12-Nov-20 | JAMA | Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19A Randomized Clinical Trial | RCT | USA | Lenze et al. | https://jamanetwork.com/journals/jama/article-abstract/2773108 | NCT04342663 | Fluvoxamine | Determine whether fluvoxamine, given during mild COVID-19 illness, prevents clinical deterioration and decreases the severity of disease |
| Preprint | The Lancet | Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial | RCT | Argentina | Krolewiecki et al. | https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3714649 | NCT004381884 | Ivermectin | Does ivermectin reduce the viral load? |
| 27-Oct | MedRxiv | Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial. | RCT | India | Bajpai et al. | https://www.medrxiv.org/content/10.1101/2020.10.25.20219337v1.full.pdf | NCT04346446 | Convalescent plasma | To compare the efficacy and safety of convalescent plasma with fresh frozen plasma (FFP) in severe COVID-19 patients |
| 21-Oct | MedRxiv | A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19 | RCT | France | Dubée et al. for the HYCOVID study group | https://www.medrxiv.org/content/10.1101/2020.10.19.20214940v1.full.pdf | NCT04325893 | Hydroxychloroquine | To evaluate the efficacy and safety of hydroxychloroquine in adult patients with mild-to-moderate COVID-19 at risk of worsening. |
| 23-Oct | MedRxiv | Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo controlled trial | RCT | Brazil | Rocco et al. | https://www.medrxiv.org/content/10.1101/2020.10.21.20217208v1.full.pdf | NCT04552483 | Nitazoxanide | To evaluate whether early nitazoxanide therapy would be effective in accelerating symptom resolution in patients with mild COVID-19. |
| 27-Oct | MedRxiv | Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq | RCT | Iraq | Hashim et al. | https://www.medrxiv.org/content/10.1101/2020.10.26.20219345v1.full.pdf | NCT04591600 | Ivermectin + Doxycycline | To test the combinational therapy of Ivermectin and Doxycycline in treating COVID-19 patients at different stages of the disease. |
| 21-Oct | MedRxiv | Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo-controlled phase 2 trial | RCT | China | Shi et el. | https://www.medrxiv.org/content/10.1101/2020.10.15.20213553v2.full.pdf | NCT04288102 | human umbilical cord-derived mesenchymal stem cells | To assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UC-MSCs) to treat severe COVID-19 patients with lung damage. |
| 26-Oct | Lancet pre-print | Umbilical Cord Mesenchymal Stem Cells for COVID-19 ARDS: A Double Blind, Phase 1/2a, Randomized Controlled Trial | RCT | USA | Lanzoni et al. | https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696875 | NCT04355728 | human umbilical cord-derived mesenchymal stem cells | To determine safety and explore efficacy of Umbilical Cord (UC)-MSC infusions in COVID-19 ARDS. |
| 01-Nov | J Antimicrob Chemother | Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis | Meta-analysis | UK/Iran | Simmons et al. | https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa418/5924537 | N/A | sofosbuvir/daclatasvir | To determine whether sofosbuvir/daclatasvir-based regimens improve clinical outcomes of patients with moderate or severe COVID-19. |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 26-Oct | Lancet pre-print | Phase 3 Trial of Coronavir (Favipiravir) in Patients with Mild to Moderate COVID-19 | RCT | Russia | Ruzhentsova et al. | https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696907 | NCT04501783 | Favipiravir | To evaluate the efficacy and safety of favipiravir for treatment of mild to moderate COVID-19 |
| 01-Nov-20 | Imunopathology and infectious diseases | Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality | RCT | USA | Salazar et al. | https://www.sciencedirect.com/science/article/pii/S0002944020303709?via%3Dihub | | Convalescent plasma | Efficacy of COVID-19 convalescent plasma transfusion for severe and/or critical COVID-19. |
| 21-Oct-20 | NEJM | Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 | RCT | USA | Stone et al. | https://www.nejm.org/doi/pdf/10.1056/NEJMoa2028836 | NCT04356937 | Tocilizumab | Does tocilizumab prevent intubation or death? |
| 20-Oct-20 | JAMA Internal Medicine | Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial | RCT | France | Hermine et al. | https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772187 | NCT04331808 | Tocilizumab | To determine whether tocilizumab (TCZ) improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia |
| 20-Oct-20 | JAMA Internal Medicine | Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 PneumoniaA Randomized Clinical Trial | RCT | Italy | Salvarani et al. | https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772186 | NCT04346355; EudraCT Identifier: 2020-001386-37. | Tocilizumab | To evaluate the effect of early tocilizumab administration |
| 01-Oct-20 | International Journal of Research in Pharmaceutical Sciences | Efficacy of umifenovir in the treatment of mild and moderate covid-19 patients | Randomized clinical study | Kyrgizstan | Yethindra et al. | https://pharmascope.org/ijrps/article/view/2839/6116 | NA | Umifenovir | To evaluate the efficacy of umifenovir in mild and moderate COVID-19 patients |
| 8 October 2020 | NEJM | Remdesivir for the Treatment of Covid-19 — Final Repor | RCT | USA | John H. Beigel, et al. | https://www.nejm.org/doi/10.1056/NEJMoa2007764 | NCT04280705 | Remdesivir | To evaluate the efficacy of remdesivir in shortening time to recovery in hospitalized COVID-19 patients. |
| 15 October 2020 | Lancet | Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial | Phase 1/2 vaccine trial | China | Shengli Xia, et al. | https://www.sciencedirect.com/science/article/pii/S1473309920308318?via%3Dihub | ChiCTR2000032459. | BBIBP-CorV | To assess the safety and immunogenicity of an inactivated SARS CoV2 vaccine |
| 15 October 2020 | MedRiXV | Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results | RCT | International | Hongchao Pan, et al. | https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1 | ISRCTN83971151 | Lopinavir/ritonavir, remdesivir, hydroxychloroquine, interferon | Are repurposed andiviral drugs effective in treating COV ID19? |
| 28 October 2020 | NEJM | SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | Phase 2 RCT | USA | Peter Chen, et al. | https://www.nejm.org/doi/10.1056/NEJMoa2029849 | NCT04427501 | Monoclonal antibody, LY-CoV555 | To assess the safety and dose response through reduction of viral load of monoclonal antibody LY-CoV555 in patients with mild or moderate COVID-19 |
| 21 October 2020 | Lancet preprint | Self-Proning in COVID-19 Patients on Low-Flow Oxygen Therapy: A Cluster Randomised Controlled Trial | RCT | Switzerland | Aileen Kharat, et al. | https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3692538 | SNCTP000003718 | Self-proning | To assess if a simple incentive to self-prone for a maximum of 12 h per day would decrease oxygen needs in patients admitted for COVID-19 pneumonia on low-flow oxygen therapy. |
| 11 September 2020 | International Forum of Allergy and Rhinology | Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with coronavirus disease 2019 | RCT | USA | Kyle S. Kimura, et al. | https://onlinelibrary.wiley.com/doi/10.1002/alr.22703 | NA | Nasal irrigations | To assess if nasal irrigation can reduce symptoms and viral shedding in mild and moderate COVID-19 patients |
| Preprint | MedRiXV | Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia | RCT | USA | Carlos Salama, et al. | https://www.medrxiv.org/content/10.1101/2020.10.21.20210203v1 | NCT04372186 | Tocilizumab | To assess the safety and efficacy of tocilizumab in patients hospitalized and non-ventilated with Covid-19 pneumonia. |
| 21 October 2020 | BMC Infectious Diseases | The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial | RCT | Iran | Naser Gharebaghi, et al. | https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05507-4 | IRCT20200501047259N1 | Immunoglobulin gamma | To evaluate the efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 infection. |
| 28 September 2020 | Lancet | Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial | RCT | Netherlands | Alexander P J Vlaar, et al. | https://www.thelancet.com/action/showPdf?pii=S2665-9913%2820%2930341-6 | NCT04333420 | Vilobelimab | Phase 2 study to explore the potential benefit and safety of IFX-1 (vilobelimab) in patients with severe COVID-19. |
| 29 September 2020 | NEJM | Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults | Vaccine trial Phase 1 | USA | Evan J. Anderson, et al. | https://www.nejm.org/doi/full/10.1056/NEJMoa2028436 | NCT04283461 | mRNA-1273 vaccine | Is the SARS CoV-2 mRNA 1273 safe and well tolerated in older adults and does it ellicit an immune response? |
| 30 September 2020 -pre-approved | Nature | COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses | Vaccine trial Phase 1 and 2 | Germany | Ugur Sahin, et al. | https://www.nature.com/articles/s41586-020-2814-7 | NCT04380701 | BNT162b1 vaccine | Does the BNT162b1 vaccine elicit both antibody and T-cell response in healthy adults? |
| Preprint | Research Square | Engineered interferon alpha effectively improves clinical outcomes of COVID-19 patients | RCT | China | Chuan Li, et al. | https://assets.researchsquare.com/files/rs-65224/v1/22886bf0-ce06-4d42-aeb6-c73ebb7c2003.pdf | ChiCTR2000029638 | Engineered interferon alpha | To evaluate the efficacy and safety of recombinant super-compound interferon versus traditional interferon alpha in patients with moderate to severe COVID-19 |
| 24 August 2020 | International Immunopharmacology | Interferonβ-1b in treatment of severe COVID-19: A randomized clinical trial | RCT | Iran | Hamid Rahmani, et al. | https://www.sciencedirect.com/science/article/pii/S1567576920323304?via%3Dihub | IRCT20100228003449N27 | Interferon β-1b | To evaluate the efficacy and safety of interferon (IFN) β-1b in the treatment of patients with severe COVID-19 |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 30 September 2020 | JAMA | Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers | RCT | USA | Benjamin S Abella, et al. | https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771265 | NCT04329923 | Hydroxychloroquine | To evaluate the efficacy of hydroxychloroquine to prevent transmission of SARS-CoV-2 in hospital-based HCWs with exposure to patients with COVID-19 using a pre-exposure prophylaxis strategy |
| 4 September 2020 | BMJ | Drug treatments for covid-19: living systematic review and network meta-analysis | Systematic review | International collaboration | Reed AC Siemieniuk, et al. | https://www.bmj.com/content/370/bmj.m2980 | NA | All treatments | To compare the effects of treatments for coronavirus disease 2019 (covid-19). |
| 15-Oct | Virus Research | Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials | Meta-analysis | USA, Japan | Yokoyama et al. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437510/pdf/main.pdf | N/A | Remdesivir | To compare the rate of clinical improvement among patients with COVID-19 who received 5-day course of remdesivir versus 10-day course of remdesivir versus standard care. |
| 06-Sep | MedRxiv | An in-depth investigation of the safety and immunogenicity of an inactivated 2 SARS-CoV-2 vaccine | Phase 1 RCT | China | Pu et el. | https://www.medrxiv.org/content/10.1101/2020.09.27.20189548v1.full.pdf | NCT04412538 | Vaccine | To investigate the safety and immunogenicity of an inactivated viral vaccine in immunized individuals in a phase I trial, especially focusing on safety with regard to the immunopathology of the vaccine. |
| 11-Oct | MedRxiv | Clearing the fog: Is Hydroxychloroquine effective in reducing Corona virus disease-2019 progression: A randomized controlled trial | RCT | Pakistan | Mehmood Kamran et al. | https://www.medrxiv.org/content/10.1101/2020.07.30.20165365v2.full.pdf | NCT04491994 | Hydroxychloroquine | To assess the efficacy of HCQ in reducing disease progression in mild COVID-19 |
| 05-Oct-20 | The Lancet | Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial | RCT | UK | Horby et al. (RECOVERY GROUP) | https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2932013-4 | ISRCTN 50189673, NCT04381936 | lopinavir/ritonavir | Whether lopinavir–ritonavir improves outcomes in patients admitted to hospital with COVID-19 |
| 20-Sep-20 | EClinicalMedicine | An open-label, randomized trial of the combination of IFN-kappa plus TFF2 with standard care in the treatment of patients with moderate COVID-19 | RCT | China | Fu et al. | https://www.sciencedirect.com/science/article/pii/S2589537020302911?via%3Dihub | ChiCTR2000030262 | IFN-κ , TFF2 | Efficacy and safety of IFN-κ and TFF2 in COVID patients. |
| 25-Sep | MedRxiv | Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial | Phase 1/2a RCT | Netherlands, Belgium, USA | Sadoff et al. | https://www.medrxiv.org/content/10.1101/2020.09.23.20199604v1.full.pdf | NCT04436276 | Vaccine: non-replicating adenovirus 26 based vector expressing the stabilized pre-fusion spike protein of SARS-CoV-2 | To evaluate the efficacy of a single vaccination of $5x10^{10}$ vp of Ad26.COV2.S |
| 21-Sep | MedRxiv | Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial | RCT | USA | Rajasingham et al. | https://www.medrxiv.org/content/10.1101/2020.09.18.20197327v1.full.pdf | NCT04328467 | Hydroxychloroquine | To determine the effectiveness of hydroxychloroquine as pre-exposure prophylaxis in healthcare workers at high-risk of SARS-CoV-2 exposure |
| 22-Sep | MedRxiv | Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical 3 Response in Covid-19 Patients with Pneumonia. A Randomized and 4 Controlled Clinical Trial | RCT | Cuba | Cruz et al. | https://www.medrxiv.org/content/10.1101/2020.09.03.20187112v2.full.pdf | IG/CIGB300I/CV/2001, ATENEA-Co-300 trial | Anti-CK2 Synthetic Peptide, CIGB-325 | To explore safety and efficacy of CIGB-325, an anti-CK2 peptide, in COVID-19 patients. |
| 15-Oct | Virus Research | Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials | Meta-analysis | USA, Japan | Yujiro Yokoyama et al. | https://www.sciencedirect.com/science/article/pii/S0168170220310443?via%3Dihub | N/A | Remdesivir | To compare the rate of clinical improvement among patients with COVID-19 who received 5-day course of remdesivir versus 10-day course of remdesivir versus standard care. |
| 24 July 2020 | Clinical Infectious Diseases | Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care | RCT vs cohort | USA | Susan A. Olender, et al. | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1041/5876045 | NCT04292899 and EUPAS34303 | Remdesivir | Efficacy of remdesivir in COVID19 patients |
| 17 November 2020 | Antimicrobial Agents Chemotherapy | A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19 | RCT | Japan | Yohei Doi, et al. | https://aac.asm.org/content/early/2020/09/16/AAC.01897-20 | jRCTs041190120 | Favipiravir | Assess the efficacy of favipiravir in asymptomatic or mild COVID19 patients in viral clearance, and resolution of symptoms |
| 24-Sep | Virology Journal | Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis | Systematic review & meta-analysis | Nepal | Dhan Bahadur Shrestha et al. | https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-01412-z | N/A | Favipiravir | To evaluate the efcacy and safety of the drug Favipiravir as a treatment for COVID-19. |
| 20 September 2020 | Thrombosis Research | Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID) | RCT | Brazil | Anna Cristina Bertoldi Lemos, et al. | https://www.thrombosisresearch.com/article/S0049-3848(20)30530-2/fulltext#%20 | REBEC RBR-949z6v | Enoxaparin, anticoagulants | To compare therapeutic enoxaparin treatment to standard prophylactic anticoagulant treatment in severe COVID19 |
| Preprint | Clinical Infectious Diseases | Treatment of COVID-19 Patients with Prolonged Post-Symptomatic Viral Shedding with Leflunomide -- a Single-Center, Randomized, Controlled Clinical Trial | RCT | China | Wang, et al | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1417/5909448 | ChiCTR 2000030058 | Leflunomide | To evaluate the efficacy and safety of leflunomide to treat COVID-19 patients with prolonged post-symptomatic viral shedding. |
| 26 August 2020 | Clinical Microbiology and Infection | Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis | Systematic Review and Meta-analysis | France, Switzerland | Thibault Fiolet, et al. | https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30505-X/fulltext | NA | Chloroquine, hydroxychloroquine, azithromycin | To assess the effect of chloroquine and hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| Preprint | MedRxIV | Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: Randomized Control Trial in Singapore | RCT | Singapore | Chaminda Jayampath Seneviratne, et al. | https://www.medrxiv.org/content/10.1101/2020.09.14.20186494v1 | NA | Mouth wash | To evaluate and compare different commercial moutwash solutions and their effect on reducing salivary viral load |
| Preprint | MedRxIV | Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial | RCT | Chile | María Elvira Balcells, et al. | https://www.medrxiv.org/content/10.1101/2020.09.17.20196212v1 | NCT04375098 | Covalescent Plasma | Evaluate the safety and efficacy of convalescent plasma and compare an early vs deferred treatement strategy |
| 19 July 2020 | Bioimpacts | Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial | RCT | Iran | Khalil Ansarin | https://bi.tbzmed.ac.ir/Article/bi-23240 | IRCT202003117046797N4 | Bromhexine | Evaluate the efficacy of bromhexine in intensive care unit (ICU) admission, mechanical ventilation, and mortality in patients with COVID-19. |
| 12-Sep-20 | Expert Review of Anti-Infective Therapy | The effect of antivirals on COVID-19: a systematic review | Systematic review | Hussain et al. | UK | https://www.tandfonline.com/doi/abs/10.1080/14787210.2021.1823832?journalCode=ierz20 | NA | Antivirals | Identify studies pertaining to antivirals in COVID-19 patients and review the clinical outcomes |
| 23 September 2020 | Clinical Infectious Diseases | Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19 | RCT | Brazil | Julio Cesar Garcia de Alencar, et al. | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1443/5910353 | | | To determine whether NAC in high doses can avoid respiratory failure in patients with Covid-19. |
| 17-Sep-20 | European Respiratory Journal | Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial | RCT | Iran | Edalatifard et al. | https://erj.ersjournals.com/content/early/2020/09/09/13993003.02808-2020 | IRCT20200404046947N1 | Methylprednisolone | Is methylprednisolone effective in treatment of COVID-19 patients? |
| 17-Sep-20 | Plos Medicine | Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project) | Meta-analysis | Denmark | Juul et al. | https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003293 | NA | NA | Effects of all treatment interventions for COVID-19 |
| 04-Sep-20 | The Lancet | Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia | CT | Russia | Logunov et al. | https://www.sciencedirect.com/science/article/pii/S0140673620318663?via%3Dihub | NCT04436471 and NCT04437875 | vaccine | Safety and immunogenicity of two formulations (frozen and lyophilised) of vaccine |
| 01-Oct-20 | International Journal of Antimicrobial Agents | Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial | RCT | Iran | Sekhavati et al. | https://www.sciencedirect.com/science/article/pii/S0924857920303411?via%3Dihub | NA | azithromycine | Can therapy with HCQ+AZM reduce the hospital length of stay in COVID-19 patients? |
| 10-Sep-20 | JAMA | Effect of Recombinant Human Granulocyte Colony–Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial | RCT | China | Cheng et al. | https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2770680 | ChiCTR2000030007 | G-CSF | Do increased peripheral blood leukocyte and lymphocyte cell counts lead to clinical improvement in patients with COVID-19? |
| 04-Sep-20 | The Lancet | Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial | RCT | Brazil | Furtado et al. | https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931862-6 | NCT04321278 | azithromycine | Would azithromycine improve clinical outcomes to COVID-19 patiets? |
| 03-Sep-20 | Journal Genenral Internal Medicine | Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis | Systematic review | India | Arunmozhimaran Elavarasi, et al. | https://link.springer.com/article/10.1007/s11606-020-06146-w | NA | Chloroquine, hydroxychloroquine | Is the use of CQ or HCQ effective and safe in reducing mortality and improving the clinical course, fever remission, and virologic clearance in COVID-19 patients? |
| November - December 2020 | Diabetes & Metabolic Syndrome: Clinical Research & Reviews | No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials" | Systematic review | India | Pathak et al. | https://www.sciencedirect.com/science/article/pii/S1871402120303362?via%3Dihub | NA | hydroxychloroquine | Is HCQ effective in milde to moderate COVID-19 patients? |
| 06-Sep-20 | Naunyn-Schmiedeberg's Archives of Pharmacology | Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis | Systematic review | China | Zang et al | https://link.springer.com/article/10.1007%2Fs00210-020-01964-5 | NA | hydroxychloroquine | Benefits and harms of HCQ in COVID-19 patients |
| 02-Sep-20 | JAMA | Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial | RCT | Brazil | Bruno M. Tomazini, et al. | https://jamanetwork.com/journals/jama/fullarticle/2770277?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2020.17021 | NCT04327401 | Dexamethasone | To determine whether intravenous dexamethasone increases the number of ventilator-free days among patients with COVID-19–associated ARDS. |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 02-Sep-20 | JAMA | Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 - A Meta-analysis | Meta-analysis | International Collaboration | Jonathan A.C., et al. | https://jamanetwork.com/journals/jama/fullarticle/2770279?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2020.17023 | PROSPERO database (CRD42020197242) | Corticosteroids | To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality. |
| 02-Sep-20 | JAMA | Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 - A Randomized Clinical Trial | RCT | France | Pierre-François Dequin, et al. | https://jamanetwork.com/journals/jama/fullarticle/2770276?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2020.16761 | NCT02517489 | Hydrocortisone | Does low-dose hydrocortisone decrease treatment failure in patients with COVID-19–related acute respiratory failure? |
| 02-Sep-20 | JAMA | Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial | RCT | UK | Derek C. Angus, et al. | https://jamanetwork.com/journals/jama/fullarticle/2770278?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2020.17022 | NCT02735707 | Hydrocortisone | To determine whether hydrocortisone improves outcome for patients with severe COVID-19. |
| 12 October 2020 | BMJ | Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial) | RCT | India | Anup Agarwal et al. and PLACID Collaborators | https://www.bmj.com/content/371/bmj.m3939 | CTRI/2020/04/024775 | Convalescent plasma | To assess the effectiveness of Convalescent plasma for the treatment of COVID-19 |
| 01-Sep | MedRxiv | Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial | RCT | Spain | Avendaño-Solà et al. | https://www.medrxiv.org/content/10.1101/2020.08.26.20182444v3.full.pdf | NCT04345523 | Convalescent plasma | To demonstrate the efficacy and safety of Convalescent Plasma used to prevent progression to severe disease or death in hospitalized patients with earlier forms of COVID-19 |
| 09-Sep | MedRxiv | Early viral clearance among COVID-19 patients when gargling with Povidone-Iodine and Essential oils - a clinical trial. | RCT | Malaysia | Nurul Azmawati Mohamed et al. | https://www.medrxiv.org/content/10.1101/2020.09.07.20180448v1.full.pdf | NCT04410159 | Gargling with 1% povidone-iodine (Betadine®), essential oils (Listerine®) or tap water | To assess the ability of regular gargling to eliminate SARS-CoV-2 in the oropharynx and nasopharynx. |
| 12/09/2020 | MedRxiv | Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia | RCT | USA | Rosas et al. | https://www.medrxiv.org/content/10.1101/2020.08.27.20183442v2.full.pdf | NCT04320615 | Tocilizumab | To investigate whether tocilizumab has clinical benefit in hospitalized patients with severe COVID-19 pneumonia. |
| 08-Sep | Engineering | Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial | RCT | China | Wu et al. | https://www.sciencedirect.com/science/article/pii/S2095809920302411?via%3Dihub | ChiCTR2000030001 | Triazavirin | To assess the efficacy of Triazavirin (TZV) for Covid-19 |
| 10-Sep | BMC Infectious Diseases. | Patient-Reported Health Outcomes After Treatment of COVID-19 with Nebulized and/or Intravenous Neutral Electrolyzed Saline Combined with Usual Medical Care Versus Usual Medical care alone: A Randomized, Open-Label, Controlled Trial. | RCT | Cuba | Delgado-Enciso et al. | https://assets.researchsquare.com/files/rs-68403/v1/e14a5067-cd36-4094-9c29-4bb66ac46805.pdf | RPCEC00000309 | neutral electrolyzed saline | To evaluate the efficacy of treatment with intravenous and/or nebulized neutral electrolyzed saline combined with usual medical care versus usual medical care alone, in ambulatory patients with COVID-19. |
| 01-Sep-20 | Computers in Biology and Medicine | Prediction of respiratory decompensation in Covid-19 patients using machine learning: The READY trial | RCT | USA | Burdick et al. | https://www.sciencedirect.com/science/article/pii/S0010482520302845?via%3Dihub | NCT04390516 | NA | NA |
| 19-Aug-20 | Journal of Medical Virology | Effectiveness of remdesivir for the treatment of hospitalized Covid-19 persons: a network meta-analysis | Review | China | Jiang et al. | https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26443 | NA | Remdesivir | Remdesivir and its clinical effect |
| 19-Aug-20 | Journal of Antimicrobial Chemotherapy | Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial | RCT | Iran | Sadeghi et al. | https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa334/5889948 | IRCT20200128046294N2 | sofosbuvir/daclatasvir | IS sofosbuvir and dalatasvir effective in COVID patients? |
| 18-Aug-20 | Stem Cell Research & Therapy | Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells | RCT | China | Shu et al. | https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01875-5 | ChiCTR2000031494 | umbilical cord mesenchymal stem cells | Are human umbilical cord mesenchymal stem cell infusion effective and safe for the treatment of severe COVID? |
| October | Journal of Steroid Biochemistry and Molecular Biology | "Effect of Calcifediol Treatment and best Available Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study | RCT | Spain | Marta Entrenas Castillo, et al. | https://www.sciencedirect.com/science/article/pii/S0960076020302764?via%3Dihub | NCT04366908 | Calcifediol | Evaluate the effect of calcifediol on ICU admission and mortality among patients hospitalized for COVID-19 |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 13 August 2020 | JAMA | Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials | Vaccine - Phase I and II | China | Shengli Xia, et al. | https://jamanetwork.com/journals/jama/fullarticle/2769612 | ChiCTR2000031809 | Inactivated vaccine | To assess the safety and immunogenicity of this whole virus inactivated vaccine |
| 21 August 2020 | JAMA | Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 | RCT | USA | Christoph D. Spinner, et al. | https://jamanetwork.com/journals/jama/fullarticle/2769871 | NCT04292730 | Remdesivir | Effect of remdesivir in patients with moderate COVID19 |
| 30 July 2020 | BMJ | Drug treatments for covid-19: living systematic review and network meta-analysis | Systematic Review | International Collaboration | Reed AC Siemieniuk, et al. | https://www.bmj.com/content/370/bmj.m2980 | NA | All treatments | Living systematic review and network meta-analysis |
| 28-Aug | MedRXiv | RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study | RCT | USA/ Germany | Walsh et al. | https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v2.full.pdf | NCT04368728 | Vaccine: RNA vaccines BNT162b1 and BNT162b2 | To assess the safety and immunogenicity of varying dose levels of vaccines BNT162b1 and BNT162b2. |
| 12 August 2020 | Clinical Infectious Diseases | Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial | RCT | Brazil | Christiane Maria Prado Jeronimo, et al. | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1177/5891816 | NCT04343729 | Methylprednisolone | Assess the efficacy of short-term methylprednisolone in patients with COVID-19 |
| 09 August 2020 | Clinical Infectious Diseases | AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial | RCT | Russia | Andrey A. Ivashchenko, et al. | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1176/5890024 | NCT04434248 | Favipiravir | Assess the efficacy and safety of favipiravir in moderate COVID19 and select the optimal dosing regimen for further evaluation (Phase III). |
| Preprint | International Journal of Infectious Diseases | SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial | | China | Fang Zheng, et al. | https://www.sciencedirect.com/science/article/pii/S120197122030597X?via%3Dihub | ChiCTR2000029496 | Novaferon | Efficacy of Novaferon and Novaferon + Lopinavir/ritonavir in moderate and severe COVID19. |
| Preprint | medRxiv | Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report. | RCT | Argentina | Mariano Duarte, et al. | https://www.medrxiv.org/content/10.1101/2020.08.04.20167205v2 | NCT04355936 | Telmisartan | Assess the anti-inflammatory effect of telmisartan in COVID-19 patients |
| 14 August 2020 | Critical Care | Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial | RCT | USA | Joseph Miller, et al. | https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03220-x | NCT04345614. | Auxora | Safety and tolerability of auxora in severe or critical COVID-19 |
| Preprint | medRxiv | Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial | Phase II vaccine RCT | China | Yanjun Zhang, et al. | https://www.medrxiv.org/content/10.1101/2020.07.31.20161216v1 | NCT04352608 | Inactiviated Vaccine | Is this SARS CoV 2 inactivated vaccine safe and well tolerated? |
| Preprint | medRxiv | Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial | RCT | Brazil | Maria IF Lopes, et al. | https://www.medrxiv.org/content/10.1101/2020.08.06.20169573v2 | RBR-8jyhxh | Colchicine | To evaluate the efficacy of colcihcine in treating severe and moderate COVID-19 |
| 2 September 2020 | NEJM | Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine | Phase I vaccine RCT | Australia | Cheryl Keech, et al. | https://www.nejm.org/doi/full/10.1056/NEJMoa2026920 | NCT04368988 | NVX-CoV2373; recombinant nanoparticle vaccine | Assess the safety and tolerability of the NVX-COV2373 recombinant vaccine in healthy subjects. |
| 23 July 2020 | NEMJ | Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 | RCT | Brazil | Alexandre B. Cavalcanti, et al. | https://www.nejm.org/doi/10.1056/NEJMoa2019014 | NCT04322123 | Hydroxychloroquine | Asses the efficacy of hydroxychloroquine with and without azithromycin in mild to moderate COVID19 |
| 6 July 2020 | Journal of Medical Virology | Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection | Systematic review | USA | Viveksandeep Thoguluva Chandrasekar, et al. | https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.26302 | NA | Hydroxychloroquine, Tocilizumab, Remdesivir, convalescent plasma, steroids, lopinavir/ritonavir | Asses overall efficacy of treatments that have been studied thus far. |
| Preprint | medRxiv | Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19 | CT | Cuba | Yayquier Díaz, et al. | https://www.medrxiv.org/content/10.1101/2020.07.24.20153833v1 | RPCEC00000311 | Itolizumab | Is itolizumab a safe and efficient treatment for COVID 19 in elderley patients? |
| Preprint | medRxiv | Efficacy and tolerability of bevacizumab in patients with severe Covid -19 | CT | China, Italy | Jiaojiao Pang, et al | https://www.medrxiv.org/content/10.1101/2020.07.26.20159756v1 | NCT04275414 | Bevacizumab | Is bevacizumab a safe and efficient treatment for severe COVID 19? |
| 29 July 2020 | EClinicalMedicine (Lancet) | A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19 | CT | China + USA | Weihui et al. | https://www.sciencedirect.com/science/article/pii/S2589537020302224 | ChiCTR2000030262 | IFN-κ plus trefoil factor 2 | To evaluate the efficacy and safety of intranasal inhalation of TFF2 and IFN-κ protein for SARS-CoV-2 infection |
| 21 July 2020 | Virologica Sinica | A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial | CT | China | Hu et al. | https://link.springer.com/article/10.1007%2Fs12250-020-00258-7 | ChiCTR 2000030058 | leflunomide | Is leflunomide effective in COVID-19 patients? |
| 20-Jul | Lancet | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial | RCT | UK | Folegatti et al. on behalf of the Oxford COVID Vaccine Trial Group | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext | ISRCTN 15281137; NCT04324606 | ChAdOx1 nCoV-19 vaccine | To assess the immunogenicity, reactogenicity, and safety of vaccination with ChAdOx1 nCoV-19 in single-dose and two-dose regimens. |
| 20-Jul | Lancet | Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial | RCT | China | Feng-Cai Zhu et al. | https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931605-6 | NCT04341389 | adenovirus type-5 (Ad5)-vectored COVID-19 vaccine | Phase 2 trial to further evaluate the immunogenicity and safety in a larger population, and to determine an appropriate dose for the efficacy study |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 12 August 2020 | Nature | Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults | Phase 1/2 trial | USA/Germany | Mulligan et al. | https://www.nature.com/articles/s41586-020-2639-4 | NCT04368728 | RNA Vaccine BNT162b1 | To assess safety, tolerability, and immunogenicity of RNA Vaccine candidate in a dose escalation study among healthy adults. |
| 20-Jul-20 | Medrxiv | Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine | Phase 1/2 trial | Germany/ USA | Sahin et al. | https://www.medrxiv.org/content/10.1101/2020.07.17.20140533v1.full.pdf | NCT04380701, EudraCT: 2020-001038-36 | RNA Vaccine BNT162b1 | To complement previous reported data by providing a detailed characterisation of antibody and T76 cell immune responses elicited by BNT162b1 vaccination. |
| 14-Jul | NEMJ | An mRNA Vaccine against SARS-CoV-2 — Preliminary Report | Phase 1 trial | USA | Jackson et al. | https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022483 | NCT04283461 | mRNA-1273 vaccine | To evaluate the safety and immunogenicity of mRNA-1273 vaccine |
| 08-Oct | NEJM | Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. | RCT | UK | Horby et al. (RECOVERY Collaborative Group) | https://www.nejm.org/doi/10.1056/NEJMoa2022926 | ISRCTN 50189673, NCT04381936 | Hydroxychloroquine | To assess the safety and efficacy of hydroxychloroquine in patients hospitalized with COVID-19 |
| 10-Jul | Medrxiv | A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19) | RCT & retrospective cohort study | Taiwan | Cheng-Pin Chen et al. | https://www.medrxiv.org/content/10.1101/2020.07.08.20148841v1.full.pdf | NCT04384380 | Hydroxychloroquine | To evaluate HCQ efficacy and tolerability in adult patients with mild to moderate COVID-19. |
| 16-Jul | Annals of Internal Medicine | Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 - A Randomized Trial | RCT | USA | Skipper et al. | https://www.acpjournals.org/doi/10.7326/M20-4207 | NCT04308668 | Hydroxychloroquine | To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients |
| Preprint | Lancet | Hydroxychloroquine Alone or in Combination with Cobicistat-Boosted Darunavir for Treatment of Mild COVID-19: A Cluster-Randomized Clinical Trial | RTC | Spain | Mitjà et al, | https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3615997 | NCT04304053 | Hydroxychloroquine, Darunavir, Cobicistat | Is early treatment with hydroxychloroquine (HCQ) with our without cobicistat/darunavir more efficacious than no-treatment for outpatients with mild Covid-19? |
| Preprint | ResearchSquare | A pragmatic randomized controlled trial reports the efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics | RCT | Norway | Magnus Nakrem Lyngbakken, et al. | https://assets.researchsquare.com/files/rs-44055/v1/3fb11155-d83c-48a0-ae74-b3cce9a5eac3.pdf | NCT04316377 | Hydroxychloroquine | To assess the effcacy and safety of hydroxychloroquine therapy on SARS-CoV-2 oropharyngeal viral kinetics in patients hospitalized with moderately severe COVID-19. |
| 11 June 2020 | Open Forum Infectious Diseases | Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19 | RCT | China | Jun Chen, et al. | https://pubmed.ncbi.nlm.nih.gov/32671131/ | NCT04252274 | Darunavir, Cobicistat | Evaluate the antiviral activity and safety of darunavir/cobicistat (DRV/c) for treating mild COVID-19 |
| 15-Jul-20 | SN Comprehensive Clinical Medicine | Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials | Systematic review & Meta-analysis | USA | Juan A. Siordia Jr et al. | https://link.springer.com/article/10.1007%2Fs42399-020-00399-6 | N/A | lopinavir/ritonavir; arbidol; hydroxychloroquine; remdesivir; tocilizumab; favipiravir; heparin; dexamethasone | To assess the current evidence regarding human controlled COVID-19 treatment trials. |
| Preprint | BMC Infectious Diseases | A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients. | RT | Bangladesh | Abu Taiub Mohammed Mohiuddin Chowdhury, et al. | https://www.researchgate.net/profile/Abu_Taiub_Mohammed_Mohiuddin_Chowdhury2/publication/342159343_A_comparative_observational_study_on_Ivermectin-_Doxycycline_and_Hydroxychloroquine-Azithromycin_therapy_on_COVID19_patients/links/5f02954c92851c52d619d95e/A-comparative-observational-study-on-Ivermectin-Doxycycline-and-Hydroxychloroquine-Azithromycin-therapy-on | NCT04434144 | Ivermectin, Doxycycline, Hydroxychloroquine, Azithromycin | Compared outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combination therapy COVID19 patients with mild to moderate disease. |
| updated 12/10/20 | Cochrane | Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review | Systematic review | International Collaboration | Piechotta V, et al. | https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub2/abstract | NA | Convalescent plasma, hyperimmune immunoglobulin | Assess the effectiveness of convalescent plasma and hyperimmune immunoglobulin for treating people with COVID19 |
| Preprint | Advanced Science | A Randomized, Open-label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, A Pilot Study | RCT | China | Zhigang Ren, et al. | https://onlinelibrary.wiley.com/doi/epdf/10.1002/advs.202001435 | ChiCTR2000029853 | Azvudine | Efficacy of azvudine in treating mild COVID19 patients |
| 24/06/2020 | JAMA Network Open: Infectious Diseases | Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019The GRECCO-19 Randomized Clinical Trial | Randomized clinical trial | Greece | Deftereos et al. | https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767593 | NCT04326790 | Colchicine | To evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with COVID-19. |
| 30-Jun-20 | The International Journal of Clinical Practice | Febuxostat Therapy in Outpatients With Suspected COVID-19: A Clinical Trial | RCT | Iran | Davoodi et al. | https://pubmed.ncbi.nlm.nih.gov/32603531/ | IRCT20190727044434N1 | Hydroxychloroquine, febuxostat | Is febuxostat effective in comparision with hydroxychloroquine? |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 17 July 2020 | NEMJ | Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report | RCT | UK | Horby et al. (RECOVERY Writing Committee) | https://www.nejm.org/doi/pdf/10.1056/NEJMoa2021436?casa_token=H8GAcaEgprUAAAAA:m_9Qlb5FCP6d6YPLPMryKLqVP0QTUouiQsD39ki_1j8u1syZDvAET7pLjZ3GbCpQSV4V62JZ8086BOdT | ISRCTN 50189673, NCT04381936 | Dexamethasone | To test the effectiveness of dexamethasone in patients hospitalized with COVID-19 |
| 18-Jun | medRxiv | GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia | RCT | Spain | Corral-Gudino et al. | https://www.medrxiv.org/content/10.1101/2020.06.17.20133579v1.full.pdf | EudraCT number: 2020-001934-37 | methylprednisolone | To determine whether a 6-day course of intravenous methylprednisolone (MP) improves outcome in patients with SARS CoV-2 infection at risk of developing Acute Respiratory Distress Syndrome (ARDS) |
| 05-Jun-20 | Science Immunology | Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 | RCT | USA | Roschewski et al. | https://immunology.sciencemag.org/content/5/48/eabd0110 | NA | Acalabrutinib | Is acalabrutinib effective in severe COVID-19 patients? |
| 8 June 2020 - Accelerated publication | Nature | Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe | Modelling | UK | Seth Flaxman, et al. | https://www.nature.com/articles/s41586-020-2405-7 | NA | Non-pharmaceutical interventions | Were the non-pharmaceutical interventions implemented in European countries effective in limiting the spread of SARS CoV-2? |
| 8 May 2020 | Nature - Leukemia | The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation | Retrospective analysis | Germany | F. La Rosée, et al. | https://www.nature.com/articles/s41375-020-0891-0 | | Ruxolitinib | Efficacy and safety of ruxolitinib in severe COVID19 |
| 8 June 2020 | Lancet Reheumatology | Canakinumab in a subgroup of patients with COVID-19 | Retrospective analysis | Italy | Claudio Ucciferri, et al. | https://www.sciencedirect.com/science/article/pii/S2665991320301673?via%3Dihub | NA | Canakinumab | Is canakinumab a safe and effective treatment against COVID19? |
| 10-Jun-20 | BMJ | Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study | Observational study | China | Min Liu et al. | https://www.bmj.com/content/369/bmj.m2195 | NA | NA | To examine the protective effects of appropriate personal protective equipment |
| 02-Jun-20 | The Lancet Digital Healt | Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study | Modelling study | UK | Gavines et al. | https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(20)30133-X/fulltext#%20 | NA | NA | What is the impact of different control measures for mitigating the burden of COVID-19 |
| 01-Jun-20 | Journal of Clinical Microbiology | Clinical performance of the Luminex NxTAG CoV Extended Panel for SARS-CoV-2 detection in nasopharyngeal specimens of COVID-19 patients in Hong Kong | Diagnostic | Hong-Kong | Jonathan Hon-Kwan Chen | https://jcm.asm.org/content/early/2020/05/29/JCM.00936-20 | NA | Nucleic acid test | Evaluation of Luminex NxTAG in COVID-19 detection |
| 26-May-20 | Clinical Microbiology and Infection | Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review | Systematic review / Meta-analysis | Australia/Sri Lanka | Rodrigo et al. | https://www.sciencedirect.com/science/article/pii/S1198743X20302937?via%3Dihub | NA | Hydroxychloroquine, chloroquine | Does hydroxychloroquine have antiviral effect? |
| 14-Jun | MedRxiv | Kinetics of the humoral immune response to SARS-CoV-2: comparative analytical performance of seven commercial serology tests | Diagnostic | Belgium | Herroelen et al. | https://www.medrxiv.org/content/10.1101/2020.06.09.20124719v2.full.pdf | N/A | Antibody test | To test the performance characteristics of seven commercially available serology tests for detection of antibodies against the SARS-CoV-2 |
| 09-Jun | MedRxiv | Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience | observational study | Cuba | Pereda et al. | https://www.medrxiv.org/content/10.1101/2020.05.29.20109199v1.full.pdf | RPCEC00000318 | Interferon alpha 2b | To assess the therapeutic efficacy of IFN-α2b in patients infected with SARS-CoV-2 |
| 10-Jun | MedRxiv | ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19 | Retrospective analysis | USA | Cepelowicz Rajter et al. | https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2.full.pdf | N/A | Ivermectin | To determine whether Ivermectin is associated with lower mortality rate in patients hospitalized with COVID-19 |
| 14-Jun | MedRxiv | First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia | prospective study with FDA emergency use IND | USA | Temesgen et al. | https://www.medrxiv.org/content/10.1101/2020.06.08.20125369v2.full.pdf | N/A | Lenzilumab | To assess the efficacy of lenzilumab therapy in patients hospitalized with severe COVID-19 pneumonia, who had clinical and/or biomarker evidence for increased risk of progression to respiratory failure. |
| 02-Jun | MedRxiv | Low levels of the prognostic biomarker suPAR are predictive of mild outcome in patients with symptoms of COVID-19 - a prospective cohort study | prospective cohort study | Denmark/USA | Eugen-Olsen et al. | https://www.medrxiv.org/content/10.1101/2020.05.27.20114678v1.full.pdf | N/A | Prognostic biomarker | To investigate whether soluble urokinase plasminogen activator receptor (suPAR) can aid in identifying patients with low risk of respiratory failure when presenting with symptoms of COVID-19. |
| 08/06/2020 | MedRxiv | Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day-7 Interim Analysis of a Registered Clinical Trial | CT | USA | Hess et al. | https://www.medrxiv.org/content/10.1101/2020.06.03.20116988v1.full.pdf | NCT: 04366791 | Low dose radiation | To determine if Low Dose-Radiation Therapy can reduce pulmonary inflammation associated with COVID-19 pneumonia. |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 02-Jun | MedRxiv | Efficacy and Safety of Leflunomide for Refractory COVID-19: An Open-label Controlled Study | CT | China | Wang et al. | https://www.medrxiv.org/content/10.1101/2020.05.29.20114223v1.full.pdf | ChiCTR2000030058 | Leflunomide | To evaluate the safety and efficacy of leflunomide for the treatment of refractory COVID-19 in adult patients. |
| 08-Jun | MedRxiv | Nano short peptide nutrition intervention on the prognosis of patients with COVID-19 | Retrospective analysis | China | Zhang et al. | https://www.medrxiv.org/content/10.1101/2020.06.03.20083980v1.full.pdf | N/A | enteral nutrition | To explore the effect of high fiber whey short peptide enteral nutrition on the prognosis of patients with COVID-19 |
| 05-Jun | MedRxiv | Ozone therapy for patients with SARS-COV-2 pneumonia: a single-center prospective cohort study | prospective cohort study | Spain/ USA/Canada | Hernández et al. | https://www.medrxiv.org/content/10.1101/2020.06.03.20117994v1.full.pdf | N/A | Ozone therapy | To determine if ozonated autohemotherapy is associated with a shorter time to clinical improvement in patients with severe COVID-19 pneumonia. |
| 02-Jun | MedRxiv | CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patients | CT | Cuba | Venegas-Rodriguez et al. | https://www.medrxiv.org/content/10.1101/2020.05.27.20110601v1.full.pdf | RPCEC00000313 | CIGB-258 immuno-modulatory peptide | To determine the effect of Center for Genetic Engineering and Biotechnology (CIGB)-258 therapy in seriously, or critically ill patients with COVID-19. |
| 02-Jun | MedRxiv | A cohort study to evaluate the effect of combination Vitamin D, Magnesium and Vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients. | Observational study | Singapore | Chuen Wen Tan et al. | https://www.medrxiv.org/content/10.1101/2020.06.01.20112334v1.full.pdf | N/A | Vitamin D, Magnesium and Vitamin B12 (DMB) | To determine the clinical outcomes of older COVID-19 patients who received Vitamin D, Magnesium and Vitamin B12 (DMB) compared to those who did not |
| 03-Jun | MedRxiv | Therapeutic Anticoagulation Is Associated with Decreased Mortality in Mechanically Ventilated COVID-19 Patients | Retrospective analysis | USA | Trinh et al. | https://www.medrxiv.org/content/10.1101/2020.05.30.20117929v1.full.pdf | N/A | anticoagulation agents | To evaluate differences in morbidity and mortality among mechanically ventilated patients with COVID-19 treated with therapeutic versus prophylactic anticoagulation |
| 21 October 2020 | Journal of Translational Medicine | Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial | CT | Italy | Perrone et al. | https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02573-9 | EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092) | Tocilizumab | To evaluate efficacy of tocilizumab in COVID-19 pneumonia patients. |
| 02/06/2020 | MedRxiv | Rapid point of care nucleic acid testing for SARS-CoV-2 in hospitalised patients: a clinical trial and implementation study | prospective clinical trial and observational study | UK/South Africa | Dami Collier, et al. | https://www.medrxiv.org/content/10.1101/2020.05.31.20114520v1.full.pdf | NCT04326387 | Nucleic acid diagnostic | To compare SAMBA II SARS-CoV-2 performance against the standard lab RTPCR test in suspected COVID-19 cases presenting to hospital, followed by a hospital-based implementation study. |
| 06-Jun | MedRxiv | Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity | Diagnostic comparison | Austria | Perkmann et al. | https://www.medrxiv.org/content/10.1101/2020.06.04.20117911v2.full.pdf | N/A | Antibody diagnostic | To compare three fully automated large-scale laboratory analyzer test systems, with particular emphasis on specificity, which is crucial for an adequate positive predictive value given the current low seroprevalence worldwide. |
| 05-Jun | MedRxiv | Implementation and evaluation of a novel real-time multiplex assay for SARS-CoV-2: In-field learnings from a clinical microbiology laboratory | Diagnostic validation study | Australia | Williams et al. | https://www.medrxiv.org/content/10.1101/2020.06.03.20117267v1.full.pdf | N/A | Nucleic acid diagnostic | To describe initial experience using a commercially-available multiplex two-step nested tandem RT-PCR assay for the detection of coronaviruses that infect humans, including SARS-CoV-2 |
| 02-Jun | MedRxiv | Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay | Diagnostic validation study | USA/Switzerland | Danh et al. | https://www.medrxiv.org/content/10.1101/2020.05.28.20105692v1.full.pdf | N/A | Diagnostic for indentifying suitable Convalescent plasma donors | To construct and validate a cell-free assay to measure neutralizing antibodies in order to identify suitable donors of convalescent plasma |
| 02-Jun | MedRxiv | Diagnostic accuracy of a host response point-of-care test for identifying COVID-19 | diagnostic clinical evaluation | UK | Clark et al. | https://www.medrxiv.org/content/10.1101/2020.05.27.20114512v1.full.pdf | ISRCTN14966673 | Diagnostic | To evaluate the real-world diagnostic accuracy of FebriDx for the identification of COVID-19 in hospitalised adults |
| August 2020 | Journal of Clinical Virology | Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: A prospective single-center study | Diagnostic assay | Spain | García et al. | https://www.sciencedirect.com/science/article/pii/S1386653220302158?via%3Dihub | NA | NA | To analyze the diagnostic performance of one serologic rapid test in COVID-19 patients |
| 06-Jun-20 | Brain, Behaviour and Imunity | Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study | Retrospective study | China | Zhang et al. | https://www.sciencedirect.com/science/article/pii/S0889159120309946 | NA | NA | Effects of sleep quality on recovery from lymphopenia and clinical outcomes in hospitalized patients with COVID-19 |
| 28 May 2020 | Drug Safety | Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment | Systematic review | UK | Miranda Davies, et al. | https://doi.org/10.1007/s40264-020-00952-1 | NA | Remdesivir | To assess the overall benefit–risk of the use of remdesivir as a treatment for COVID-19 compared with standard of care, placebo or other treatments |
| 27 May 2020 | Society of Critical Care | Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019 | Observational study | USA | Thomas K. Maatman, et al. | DOI: 10.1097/CCM.0000000000004466 | NA | Venous thromboembolism prophylaxis | To determine the frequency of venous thromboembolism (VT) in critically ill COVID19 patients who recieved prophylaxis for VT. |
| 3 June 2020 | JAMA | Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 - A Randomized Clinical Trial | RCT | China | Ling Li, et al. | doi:10.1001/jama.2020.10044 | ChiCTR2000029757 | Convalescent Plasma | Is convalescent plasma a safe and efficient treatment for severe COVID19? |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| Preprint | Journal of the American College of Cardiology | Ramipril in High Risk Patients with COVID-19 | Retrospective analysis | Spain | Ignacio J. Amat-Santos, et al. | https://www.sciencedirect.com/science/article/pii/S0735109720355395X?via%3Dihub | NCT03201185 (source RCT) | Ramipril | To analyze if ramipril modifies the risk for COVID-19. |
| 3 June 2020 | PlosOne | The need of health policy perspective to protect Healthcare Workers during COVID-19 pandemic. A GRADE rapid review on the N95 respirators effectiveness | Systematic review / Meta-analysis | Italy | Primiano Iannone, et al. | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0234025 | NA | N95 respirators | Should health care workeers wear surgical masks or N95 respirators during the routine care (not involving aerosol generating procedures) of COVID-19 suspected or affected patients? |
| 1 June 2020 | Lancet | Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis | Systematic review | International collaboration | Derek K Chu, et al. | https://doi.org/10.1016/S0140-6736(20)31183-1 | PROSPERO: CRD42020177047 | PPE | Investigate the effects of physical distance, face masks, and eye protection on virus transmission in health-care and non-health-care (eg, community) settings |
| Preprint | Diabetes, obesity & metabolism | Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes. A case-control study | Case population study | Italy | Gian Paolo Fadini, et al. | https://pubmed.ncbi.nlm.nih.gov/32463179/ | NA | DPP-4 inhibitors | Do DPP-4 inhinbitors have a protective effect agains COVID19? |
| 03 June 2020 | NEJM | A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 | RCT | USA / Canada | D.R. Boulware, et al. | https://www.nejm.org/doi/full/10.1056/NEJMoa2016638 | NCT04308668. | Hydroxychloroquine | Is hydroxychloroquine effective in post-exposure prohylaxis therapy? |
| Preprint | Biosensors and Bioelectronics | Ultra-sensitive and high-throughput CRISPR-Powered COVID-19 diagnosis | Diagnostic assay | USA | Zhen Huang, et al. | https://doi.org/10.1016/j.bios.2020.112316 | NA | CRISPR RT-PCR | Can CRISPR technology simplify RT-PCR for SARS CoV2 and be effective for diagnos? |
| Preprint | Gastroenterology | Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study | Retrospective study | USA | Daniel E. Freedberg, et al. | https://www.gastrojournal.org/article/S0016-5085(20)34706-5/fulltext | NA | Famotidine | Do COVID19 patients taking famotidine have a lower risk of intubation and/or death? |
| 27 May 2020 | NEJM | Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | RCT | International collaboration / Gilead Sciences | Jason D. Goldman, et al. | https://www.nejm.org/doi/full/10.1056/NEJMoa2015301 | NCT04292899 | Remdesivir | Is a 5 day course of remedesivir as effective as a 10 course in treating moderately ill COVID19 patients? |
| 22 May 2020 | NEJM | Remdesivir for the Treatment of Covid-19 — Preliminary Report | RCT | International collaboration | J.H. Beigel, et al. | https://www.nejm.org/doi/full/10.1056/NEJMoa2007764 | NCT04280705 | Remdesivir | Is remdesivir an effective treatment for reducing time to recovery in COVID19 patients? |
| Preprint | Journal of Allergy and Clinical Immunology | Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial | RCT | China | Yang Cao, et al. | https://doi.org/10.1016/j.jaci.2020.05.019 | ChiCTR-OPN-2000029580. | Ruxolitinib | To evaluate the efficacy and safety of ruxolitinib for patients with severe COVID19. |
| Preprint | Clinical Infectious Diseases | Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID 19 by restoration of lymphocytopenia and reversion of exhausted T cells | Retrospective study | China | Yueping Liu, et al. | https://pubmed.ncbi.nlm.nih.gov/32442287/ | NA | Thymosin alpha | Is thymosin alpha a safe and effective treatment for severe COVID19? |
| Preprint | International Journal of Infectious Diseases | HUMAN CORONAVIRUS DATA FROM FOUR CLINICAL TRIALS OF MASKS AND RESPIRATORS | Review | Australia | C Raina MacIntyre, et al. | https://www.sciencedirect.com/science/article/pii/S1201971220303994 | NA | PPE | Level of protection confered by masks and respirators for common coronavirus. |
| 29-May-20 | The Lancet Rheumatology | Anakinra for severe forms of COVID-19: a cohort study | Cohort study | France | Huet et al. | https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30164-8/fulltext | NA | Anakinra | Use of anakinra in patients who were admitted to hospital for severe forms of COVID-19 |
| 22-May-20 | The Lancet | Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial | CT | China | Feng-Cai Zhu et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext | NCT04313127 | Ad5 vectored COVID-19 vaccine | Are different doses of Ad5 vectored COVID-19 vaccine safe and immunogenic? |
| 29-May-20 | Preprint | A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19 | Comparative study | China | Zhicheng Zhang et al. | https://www.researchsquare.com/article/rs-28376/v1.pdf | NA | Danopevir and lopinavir/ritonavir | Antiviral effect of danopevir or lopinavir/ritonavir in COVID-19 patients |
| 01-Jun-20 | Current Medical Science | Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission–A Preliminary Report of a Retrospective Cohort Study | Observational study | China | Zhang et al. | https://link.springer.com/content/pdf/10.1007/s11596-020-2203-3.pdf | NA | Arbidol | Is Arbidol effective in profylaxis of COVID? |
| 26-May-20 | Advanced Journal of Emergency Medicine | Interferon beta-1a as a Candidate for COVID-19 Treatment; An Open-label Single-Arm Clinical Trial | CT | Iran | Payandemehr et al. | http://ajem.tums.ac.ir/index.php/ajem/article/view/454/307 | IRCT20150914024017N1 | Interferon beta1a | Is interferon beta1a effective in treatment of COVID-19? |
| 13 July 2020 | Antiviral Agents | Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial | RCT | Iran | Davoudi-Monfared et al. | https://aac.asm.org/content/early/2020/07/08/AAC.01061-20 | IRCT20100228003449N28 | Interferon beta-1a | To evaluate efficacy and safety of IFN β-1a in patients with severe COVID-19. |
| 30/05/2020 | medRxiv | A serological assay to detect SARS-CoV-2 antibodies in at-home collected fingerprick dried blood spots | Clinical Evaluation of diagnostic test | USA | Karp et al. | https://www.medrxiv.org/content/10.1101/2020.05.29.20116004v2.full.pdf | IRB protocol #20180015 | Antibody diagnostic test | To develop and clinically evaluate an at-home finger-prick dried blood spot test to detect SARS-CoV-2 antibodies |
| 27/05/2020 | medRxiv | Performance evaluation of the point-of-care SAMBA II SARS-CoV-2 Test for detection of SARS-CoV-2 | Clinical Evaluation of diagnostic test | UK/USA/South Africa | Assennato et al. | https://www.medrxiv.org/content/10.1101/2020.05.24.20100990v2.article-info | N/A | Nucleic acid diagnostic test | To assess the analytical and clinical performance of the SAMBA II 83 SARS-CoV-2 Test using panels and clinical samples. |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 30/05/2020 | medRxiv | EasyCOV : LAMP based rapid detection of SARS-CoV-2 in saliva | Clinical Evaluation of diagnostic test | France | L'Helgouach et al. | https://www.medrxiv.org/content/10.1101/2020.05.30.20117291v1.full.pdf | N/A | saliva RT-LAMP diagnostic test | To develop and clincally evaluate a new simple saliva SARS-CoV-2 detection test based on RT-LAMP technology |
| 27/05/2020 | medRxiv | Evaluation of performance of two SARS-CoV-2 Rapid whole-blood finger-stick IgM-IgG Combined Antibody Tests | Clinical Evaluation of diagnostic test | France | Prazuck et al. | https://www.medrxiv.org/content/10.1101/2020.05.27.20112888v1.full.pdf | N/A | Antibody rapid diagnostic test | To evaluate the performance of two COVID 19 IgM/IgG Rapid Diagnostic Tests compared to the gold standard, RT-PCR. |
| 29/05/2020 | medRxiv | Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial | proof of concept study | Italy | Perotti et al. | https://www.medrxiv.org/content/10.1101/2020.05.26.20113373v1.full.pdf | NCT 04321421 | convalescent plasma | To show the potential efficacy and safety of hyperimmune plasma infusions, obtained from convalescent donors, in COVID-19 patients with respiratory failure |
| 26/05/2020 | medRxiv | Use of High Flow Nasal Therapy to Treat Moderate to Severe Hypoxemic Respiratory Failure in COVID-19 | Retrospective analysis | USA | Patel et al. | https://www.medrxiv.org/content/10.1101/2020.05.22.20109355v1.full.pdf | | High Flow Nasal Therapy | To analyse the outcomes of COVID-19 patients with moderate-to-severe hypoxemic respiratory failure receiving High Flow Nasal Therapy |
| 22-May-20 | The Lancet | Hydroxychloroquine or chloroquine with or without a with or without a macrolide for treatment of COVID-19: a multinational registry analysis | Observational study | USA/Switzerland | Mehra et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext | NA | Hydroxychloroquine | Are these treatment regimens associated with in-hospital death? |
| 15 May 2020 | Frontiers in Immunology | Interferon-a2b Treatment for COVID-19 | CT | Canada, China | Qiong Zhou, et al. | https://www.frontiersin.org/articles/10.3389/fimmu.2020.01061/full | NA | Interferon-a2b | Is Interferon-a2b efficient in accelerating viral clearance and reducing inflammation markers? |
| 19 May 2020 | Clinical Infectious Diseases | Early Short Course Corticosteroids in Hospitalized Patients with COVID-19 | Retrospective study | USA | Fadel et al. | https://www.medrxiv.org/content/10.1101/2020.05.04.20074609v1.full.pdf | NCT04374071 | corticosteroids | To examine the role of early corticosteroid therapy in patients with moderate to severe COVID-19. |
| Preprint | medRxiv | Convalescent plasma treatment of severe COVID-19: A matched control study | CT | USA | Sean T. H. Liu, et al. | https://www.medrxiv.org/content/10.1101/2020.05.20.20102236v1 | NA | Convalescent plasma | Is convalescent plasma an effective treatment for severe COVID19? |
| 14 May 2020 | Lancet | Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study | Case population study | Spain | Francisco J de Abajo, et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31030-8/fulltext | EUPAS34437 | renin–angiotensin–aldosterone system inhibitors, RAAS | Does use of RAAS predispose patients to severe COVID19? |
| Preprint | Cardiology Journal | Resuscitation of the patient with suspected/confirmed COVID-19 when wearing personal protective equipment: A randomized multicenter crossover simulation trial | Randomized crossover trial | Poland | Marek Malysz, et al. | https://journals.viamedica.pl/cardiology_journal/article/view/68336 | NA | PPE | To evaluate various methods of chest compressions in patients with suspected/confirmed SARS-CoV-2 infection conducted by medical students wearing full personal protective equipment (PPE) for aerosol generating procedures (AGP). |
| 15 May 2020 | NEJM | Compassionate Use of Remdesivir in Covid-19 (Grein et al. - NEMJ) | Letters to the editor | International | Stefano Bonovas, Gerd Fätkenheuer, Christian Hoffman, Jiayuan Wu | https://www.nejm.org/doi/full/10.1056/NEJMc2015312 | NA | Remdesivir | Re-analysis of cumulative incidence of improvement, patient classification |
| Preprint | Clinical Microbiology and Infection | A multiple center clinical evaluation of an ultra-fast single-tube assay for SARS-CoV-2 RNA | Diagnostic clinical evaluation | China | Ji Wang, et al. | https://www.clinicalmicrobiologyandinfection.com/action/showPdf?pii=S1198-743X%2820%2930284-6 | NA | Diagnostic test | To evaluate the performance of an ultra-fast single-tube nucleic acid isothermal amplification detection assay for SARS-CoV-2 RNA |
| Preprint | Journal of Clinical Virology | A combined oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of SARS-CoV-2 | Diagnostic assay comparison | Canada | Jason J., et al. | https://www.sciencedirect.com/science/article/pii/S1386653220301840 | NA | Oropharyngeal/nares and nasopharyngeal swabs | Are combined oropharyngeal/nares swab is a suitable alternative for nasopharyngeal swabs for COVID19 sample colleciton? |
| 19 May 2020 | Nature | Artificial intelligence–enabled rapid diagnosis of patients with COVID-19 | Diagnostic assay | Chinq | Xueyan Mei, et al. | https://www.nature.com/articles/s41591-020-0931-3 | N/A | AI diagnostic algorithm | Can an AI model rapidly identify SARS-CoV-2 infection based on initial chest CT scans and associated clinical information of COVID-19 (+) patients in the early stage? |
| 23-May | Medrxiv | Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19 | retrospective analysis | South Korea | Sang Youl Rhee et al. | https://www.medrxiv.org/content/10.1101/2020.05.20.20108555v1.full.pdf | N/A | dipeptidyl peptidase-4 (DPP-4i), renin–angiotensin system (RAS) blockade | To investigate the effects of dipeptidyl peptidase-4 (DPP-4i) and renin–angiotensin system (RAS) blockade on the short-term clinical outcomes of COVID-19 |
| 22-May | Medrxiv | Do COVID-19 patients admitted to the ICU require anti-Pneumocystis jirovecii prophylaxis? | prospective cohort study | France | Alanio | https://www.medrxiv.org/content/10.1101/2020.05.18.20105296v1.full.pdf | N/A | anti-Pneumocystis jirovecii prophylaxis | To investigate the prevalence of Pneumocystis jirovecii in COVID-19 patients admitted to the ICU |
| 23/05/2020 | Medrxiv | Development and clinical application of a rapid and sensitive loop-mediated isothermal amplification test for SARS-CoV-2 infection | Diagnostic | China | Hu et al. | https://www.medrxiv.org/content/10.1101/2020.05.20.20108530v2 | N/A | RT-LAMP Diagnostic test | To develop and validate a novel RT-LAMP assay capable of detecting SARS-CoV-2 RNA for potential use in centralized facilities and point-of-care settings |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 22 May 2020 | Medrxiv | Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support | retrospectiv e analysis | Italy, UK | Gritti et al. | https://www.medrxiv.org/content/10.1101/2020.04.01.20048561v3.full.pdf | NCT04322188 | siltuximab | Efficacy of siltuximab for treatment of severe patients with COVID-19 |
| 22-May | Medrxiv | Almitrine as a non ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients | Case control series | France | Losser et al. | https://www.medrxiv.org/content/10.1101/2020.05.18.20105502v1.full.pdf | N/A | Almitrine | To test if intravenous almitrine can improve hypoxia in mechanically ventilated COVID-19 patients. |
| 12-May | MedRxiv | Remdesivir in treatment of COVID-19: A systematic benefit-risk assessment | Systematic benefit-risk assessment | UK | Davies et al. | https://www.medrxiv.org/content/10.1101/2020.05.07.20093898v1.full.pdf | N/A | Remdesivir | To examine the benefit-risk profile of remdesivir in COVID-19 patients compared to standard of care, placebo or other treatments. |
| 15-May | MedRxiv | Assisting Scalable Diagnosis Automatically via CT Images in the Combat against COVID-19 | Application of deep learning to retrospectiv e analysis | China | Liu et al. | https://www.medrxiv.org/content/10.1101/2020.05.11.20093732v1.full.pdf | N/A | Chest CT | To test the hypothesis that application of deep learning to 3D chest CT images could help identify COVID-19 infections. |
| 15-May | MedRxiv | The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents | retrospectiv e analysis | Belgium | De Spiegeleer et al. | https://www.medrxiv.org/content/10.1101/2020.05.11.20096347v1.full.pdf | N/A | ARBs, ACEi, Statins | To explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19 infected older people residing in nursing homes. |
| 14-May | MedRxiv | Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients | expanded access program | USA | Joyner et al. | https://www.medrxiv.org/content/10.1101/2020.05.12.20099879v1.full.pdf | NCT04338360 | Convalescent plasma | To analyse key safety metrics following transfusion of convalescent plasma in patients with severe or life-threatening COVID-19 |
| 15-May | MedRxiv | Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series | retrospectiv e case study | USA | Weber et al. | https://www.medrxiv.org/content/10.1101/2020.05.13.20087734v1.full.pdf | NCT04387786 | Nebulized in-line endotracheal Dornase Alfa | To report the clinical course, safety, and outcomes after nebulized in-line endotracheal dornase alfa treatment for intubated and mechanically ventilated patients with COVID-19. |
| 13-May | MedRxiv | Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas | Case series | USA | Salazar et al. | https://www.medrxiv.org/content/10.1101/2020.05.08.20095471v1.full.pdf | N/A | Convalescent plasma | To determine if transfusion of convalescent plasma is a safe treatment option for those with severe COVID-19 disease. |
| 30 April 2020 | Journal of Virus Eradication | A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? | Systematic review | UK | Victoria Pilkington, et al. | http://viruseradication.com/journal-details/A_review_of_the_safety_of_favipiravir_%E2%80%93_a_potential_treatment_in_the_COVID-19_pandemic%5E/ | NA | Favipiravir | Safety of favipiravir |
| 12 May 2020 | Basic Research in Cardiology | Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series | Case series | USA | Siddharth Singh, et al. | https://link.springer.com/article/10.1007/s00395-020-0795-1 | NA | CAP-1002 | To evaluate the safety and impact of administration of allogeneic CDCs, formulated for intravenous (IV) infusion as CAP-1002, in critically ill COVID-19 patients. |
| Preprint | Canadian Medical Association Journal | Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis | Systematic Review ; Meta-analysis | International Collaboration | Zhikang Ye, et al. | https://www.cmaj.ca/content/cmaj/early/2020/05/14/cmaj.200645.full.pdf | NA | Corticosteroids | Assess efficacy and safety of corticosteroids for COVID19, SARS, MERS, CAP, ARDS and influenza |
| 1 May 2020 | Clinical and Experimental Rheumatology | Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 | CT | Italy | S. Sciascia, et al. | https://www.clinexprheumatol.org/abstract.asp?a=15723 | NA | Tocilizumab | To assess the efficacy and safety of tocilizumab in severe COVID19 patients |
| 23 April 2020 | BMJ Global Health | Facial protection for healthcare workers during pandemics: a scoping review | Scoping Review | USA | Laura R Garcia Godoy, et al. | https://gh.bmj.com/content/5/5/e002553 | NA | Facial protection | Efficacy of different facial protection devices, especially in light of N95 respirator shortages |
| Preprint | Pharmacological Research | Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post treatment hospitalisation status | Case series | Italy | Spinello Antinori, et al. | https://pubmed.ncbi.nlm.nih.gov/32407959/ | NA | Remdesivir | Comparative efficacy of remdesivir in ICU and non-ICU patients |
| 15 April 2020 | Cochrane Library | Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff | Systematic Review | International Collaboration | Verbeek JH, et al. | https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011621.pub4/full | NA | PPE | To evaluate which type of full-body PPE and which method of donning or do.ing PPE have the least risk of contamination or infection for HCW, and which training methods increase compliance with PPE protocols. |
| 14 May 2020 | Cochrane Library | Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review | Systematic Review | Netherlands | Valk SJ, et al. | https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600/full | NA | Convalescent Plasma | To assess whether convalescent plasma or hyperimmune immunoglobulin transfusion is eJective and safe in the treatment of people with COVID-19. |
| Preprint | Journal of Allergy and Clinical Immunology | Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease | Case series | Italy | Emanuele Pontali, et al. | https://www.jaci-online.org/article/S0091-6749(20)30634-5/fulltext | NA | Anakinra | Preliminary assessment of the safety and efficacy of anakirna in severe/moderate COVID19 |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 09 May 2020 | Microorganisms | Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results From SMAtteo COvid19 REgistry (SMACORE) | Observational study | Italy | Colaneri et al. | https://pubmed.ncbi.nlm.nih.gov/32397399/ | NA | tocilizumab | What is the role of tocilizumab therapy in severe COVID-19 patients? |
| 14 May 2020 | BMJ | Hydroxychloroquine in Patients With Mainly Mild to Moderate Coronavirus Disease 2019: Open Label, Randomised Controlled Trial | RCT | China | Tang et al. | https://www.bmj.com/content/369/bmj.m1849.long | ChiCTR2000029868 | Hydroxychloroquine | Is hydroxychloroquine effective and safe in COVID-19 patients? |
| 05 May 2020 | BMJ | Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data | Observational study | France | Mahévas et al. | https://www.bmj.com/content/369/bmj.m1844 | NA | Hydroxychloroquine | Is hydroxychloroquine effective? |
| 08 May 2020 | MedRxiv | Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients | Clinical Evaluation of diagnostic test | France | Tuaillon et al. | https://www.medrxiv.org/content/10.1101/2020.05.04.20090027v3.full.pdf | NCT04347850 | Antibody diagnostic test | To assess and compare the performance of 6 rapid tests and 3 ELISAs for the diagnosis of COVID-19, and to explore seroconversions in subjects with confirmed COVID-19 |
| 08 May 2020 | MedRxiv | ddPCR: a more sensitive and accurate tool for SARS-CoV-2 detection in low viral load specimens | Clinical evaluation of diagnostic test | China | Suo et al. | https://www.medrxiv.org/content/10.1101/2020.02.29.20029439v2.full.pdf | | PCR diagnostic test | To compare the dynamic range and the limit of detection (LoD) between ddPCR and RT-PCR |
| 05 May 2020 | MedRxiv | Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: an Exploratory Randomized, Controlled Trial | RCT | China | Yan Lou et al. | https://www.medrxiv.org/content/10.1101/2020.04.29.20085761v1.full.pdf | ChiCTR2000029544 | baloxavir marboxil, favipiravir | To evaluate the efficacy and safety of adding baloxavir marboxil or favipiravir to the current standard antiviral treatment |
| 11 May 2020 | MedRxiv | Celebrex adjuvant therapy on COVID-19: An experimental study | Clinical trial | China | Wenxin Hong et al. | https://www.medrxiv.org/content/10.1101/2020.05.05.20077610v1.full.pdf | ChiCTR2000031630 | Celebrex (Celecoxib) | To determine if excessive PGE2 may be a key in the pathology of COVID-19 and whether COX-2 is a critical target for therapy. |
| 05 May 2020 | MedRxiv | COVID-19 Related Mortality: Is the BCG Vaccine Truly Effective? | retrospective analysis of International mortality rates | Mexico | Paredes et al. | https://www.medrxiv.org/content/10.1101/2020.05.01.20087411v1.full.pdf | N/A | BCG | To take into account the possible confounders when analyzing the difference in mortality rates between countries with and without history of a universal BCG vaccination program. |
| 08 May 2020 | MedRxiv | Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients | retrospective observational study | USA | Carlucci et al. | https://www.medrxiv.org/content/10.1101/2020.05.02.20080036v1.full.pdf | N/A | zinc sulfate (as add-on therapy to hydroxychloroquine and azithromycin) | To determine if zinc sulfate added to hydroxychloroquine and azithromycin may improve outcomes among hospitalized patients. |
| 05 May 2020 | MedRxiv | Efficacy of face mask in preventing respiratory virus transmission: a systematic review and meta-analysis | Systematic review and meta-analysis | China | Liang et al. | https://www.medrxiv.org/content/10.1101/2020.04.03.20051649v3.full.pdf | N/A | facemask | To evaluate the effectiveness of the use of masks to prevent laboratory-confirmed respiratory virus transmission. |
| 5 May 2020 | Nature | Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis | Meta-analyisis | China | Huan Li, et al. | https://www.nature.com/articles/s41375-020-0848-3.pdf | NA | Corticosteroids | Evaluate the safety and efficacy of corticosteroids on SARS-CoV-2, SARS-CoV, and MERS-CoV infections |
| Preprint | Journal of Biomedical and Health Informatics | In Silico Trial to test COVID-19 candidate vaccines: a case study with UISS platform | Giulia Russo, et al. | Italy | Giulia Russo, et al. | https://www.biorxiv.org/content/10.1101/2020.05.06.080630v1.full.pdf | NA | Vaccine | Can an efficient in-silico trial base be developed, and can it evaluate vaccine candidates? |
| Preprint | Nature | Effect of non-pharmaceutical interventions to contain COVID-19 in China | Mathematical Modeling | China, UK, US | Shengjie Lai, et al. | https://www.nature.com/articles/s41586-020-2293-x_reference.pdf | NA | Non-pharmaceutical interventions | Were non-pharmaceutical interventions effective in reducing the number of cases and speed of the epidemic in mainland China? |
| 29 April 2020 | Autoimmunity Reviews | Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis | Retrospective analysis | Israel | Omer Gendelman, et al. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198406/ | NA | Colchicine, hydroxychloroquine | Protective role of colchicine or hydroxychloriquine for COVID19 infection |
| Preprint | Autoimmunity Reviews | Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy | Observational study | Italy | Paola Toniati, et al. | https://www.sciencedirect.com/science/article/abs/pii/S1568997220301300 | NA | Tocilizumab | Is tocilizumab effective for improving respiratory condition in severe COVID19? |
| April 29 2020 | PNAS | Effective treatment of severe COVID-19 patients with tocilizumab | Retrospective analysis | China | Xiaoling Xua, et al. | https://www.pnas.org/content/pnas/early/2020/04/27/2005615117.full.pdf | | Tocilizumab | Efficacy and safety of tocilizumab in sever COVID19 |
| 08 May 2020 | The Lancet | Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial | RCT | Hong Kong | Hung et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext | NCT04276688 | interferon beta-1b, lopinavir–ritonavir, ribavirin | The efficacy and safety of combination |
| 07 May 2020 | The Lancet Rheumatology | Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study | Observational study | Italy | Cavalli et al. | https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30127-2/fulltext | NCT04318366 | anakinra | Efficacy of anakinra |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 19 April 2020 | Journal of Clinical Virology | Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review | Systematic Review | USA | Alzghari et al. | https://www.sciencedirect.com/science/article/pii/S1386653220301220?via%3Dihub | NA | NA | Outcomes associated with TCZ treatment in patients with COVID-19 |
| 25 April 2020 | Clinical Microbiology and Infection | Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study | Retrospective CT | China | N. Lian, et al. | https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30234-2/fulltext | NA | Umifenovir (Arbidol) | Effectiveness and safety of umifenovir for moderate COVID-19 |
| 16 April 2020 | Journal of Infection | Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact | CT | Italy | Fabrizio Cantini, et al. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177073/ | NA | Baricitinib | Is Baricitinib an effective drug for clinical and respiratory improvement in moderate COVID19 patients? |
| 04 May 2020 | medRxiv | Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19 | growth curve analysis | USA | Berg et al. | https://www.medrxiv.org/content/10.1101/2020.04.05.20054163v5.full.pdf | N/A | BCG vaccination | Does BCG vaccination serve as a protective factor against COVID-19 |
| 22 April 2020 | medRxiv | Does TB Vaccination Reduce COVID-19 Infection? No Evidence from a Regression Discontinuity Analysis | regression analysis based on observational data | USA/ Japan | Fukui et al. | https://www.medrxiv.org/content/10.1101/2020.04.13.20064287v1.full.pdf | N/A | BCG vaccination | To assess the effectiveness of BCG vaccination against COVID-19 |
| 29 April 2020 | medRxiv | A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19 | RCT | China | Fang Zheng et al. | https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1.full.pdf | ChiCTR2000029496 | Novaferon, Lopinavir/Ritonavir | To determine the antiviral effects of Novaferon for COVID-19 |
| 01 May 2020 | medRxiv | Review and methodological analysis of trials currently testing treatment and prevention options for the novel coronavirus disease (COVID-19) globally. | Systematic review | Greece, France | Fragkou et al. | https://www.medrxiv.org/content/10.1101/2020.04.27.20080226v1.full.pdf | N/A | all treatment and preparation options for covid-19 | To summarise the data on all currently tested treatment and prevention options for COVID-19, and to methodologically analyse and evaluate the quality of the registered interventional studies |
| 01 May 2020 | medRxiv | Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19 | retrospective analysis | China | Bo Yu et al. | https://www.medrxiv.org/content/10.1101/2020.04.27.20073379v1.full.pdf | N/A | Hydroxychloroquine | Could hydroxychloroquine administration be beneficial in the treatment of critically ill patients with COVID-19? |
| 29 April 2020 | medRxiv | Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19 | retrospective analysis | USA | Ip et al. | https://www.medrxiv.org/content/10.1101/2020.04.24.20077388v1.full.pdf | N/A | anti-hypertensive agents | To determine if anti-hypertensive drugs are harmful or beneficial to Covid-19 patients with hypertension |
| 29 April 2020 | medRxiv | Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study | retrospective analysis | China | Xiu Lan et al. | https://www.medrxiv.org/content/10.1101/2020.04.25.20079079v1.full.pdf | N/A | lopinavir/ritonavir, arbidol | To evaluate the antiviral efficacy of lopinavir/ritonavir alone or combined with arbidol in the treatment of hospitalized patients with COVID-19. |
| 04 May 2020 | medRxiv | Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19 | prospective observational study | China | Mingxing Huang et al. | https://www.medrxiv.org/content/10.1101/2020.04.26.20081059v1.full.pdf | (ChiCTR2000029609 | Chloroquine | To assess the efficacy and safety of chloroquine with different doses in COVID-19 |
| 01 May 2020 | medRxiv | QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin | retrospective analysis | USA/Italy | Chorin et al. | https://www.medrxiv.org/content/10.1101/2020.04.27.20074583v1.full.pdf | N/A | Hydroxychloroquine, Azithromycin | To evaluate the effects of Hydroxychloroquine/Azithromycin on the QT interval and the arrhythmic risk in patients with SARS-CoV-2 infection. |
| 01 May 2020 | medRxiv | Performance & Quality Evaluation of Marketed COVID-19 RNA Detection Kits | diagnostic kit evaluation | China | David Surace Kapitula et al. | https://www.medrxiv.org/content/10.1101/2020.04.25.20080002v1.full.pdf | N/A | qPCR Diagnostic test | To assess and compare all nucleic acid-based COVID-19 testing kits from quality control perspectives |
| 29 April 2020 | medRxiv | Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: a systematic review | Systematic review | USA/Canada | Michaud et al. | https://www.medrxiv.org/content/10.1101/2020.04.21.20066761v2.full.pdf | N/A | azithromycin, chloroquine, favipiravir, hydroxychloroquine, lopinavir/ritonavir, remdesivir | To determine the relative risk of drug-induced Long QT Syndrome (LQTS) associated with SARS-CoV-2 (COVID-19) proposed repurposed drugs compared to well-known torsadogenic compounds |
| 29 April 2020 | medRxiv | Concentration-dependent mortality of chloroquine in overdose | retrospective analysis, Bayesian logostic regression, pharmacodynamic modelling | Thailand/ UK/ France | Watson et al. | https://www.medrxiv.org/content/10.1101/2020.04.24.20078303v1.full.pdf | N/A | Chloroquine | To evaluate the risk of overdose for chloroquine treatment or prevention regimens currently being trialled in COVID19 |
| 29 April 2020 | The Lancet | Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial | RCT | China | Wang et al. | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext | NCT04257656 | remdesivir | Effect of remdesivir in COVID-19 patients |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 02 May 2020 | Academic Emergency Medicine | A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. | Systematic review | USA | Chowdhury et al. | https://onlinelibrary.wiley.com/doi/abs/10.1111/acem.14005 | NA | NA | Analyze current literature to find the role of CQ and HCQ |
| 20 April 2020 | medRxiv | Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A Multicenter Retrospective Cohort Study | retrospective cohort study | China | Ziyun Shao et al. | https://www.medrxiv.org/content/10.1101/2020.04.11.20061739v2.full.pdf | N/A | intravenous immunoglobulin (IVIG) therapy | To determine the clinical efficacy of intravenous immunoglobulin (IVIG) therapy in COVID-19 patients. |
| 22 April 2020 | Clin Pharmacol Ther. | Chloroquine dosing recommendations for pediatric COVID-19 supported by modeling and simulation. | pharmacokinetic (PBPK) model | Netherlands | Verscheijden et al. | https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1864 | N/A | Chloroquine | To establish best-evidence to inform pediatric Chloroquine doses for children infected with COVID-19 |
| 24 April 2020 | JAMA Network Open | Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. | RCT | Brazil | Borba et al | https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765499 | NCT04323527 | Chloroquine | To evaluate the safety & efficacy of different dosages of chloroquine in patients with severe COVID-19. |
| 21 April 2020 | medRxiv | A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019（COVID-19） | RCT | China | Zhong et al. | https://www.medrxiv.org/content/10.1101/2020.04.15.20066266v1.full.pdf | ChiCTR2000029851 | α-Lipoic acid (ALA) | To evaluate the clinical efficacy and safety of α-Lipoic acid (ALA) for critically ill patients with COVID-19. |
| 22 April 2020 | medRxiv | Effectiveness and Safety of Glucocorticoids to Treat COVID-19: A Rapid Review and Meta-Analysis | Rapid review and meta-analysis | China | Shuya Lu et al | https://www.medrxiv.org/content/10.1101/2020.04.17.20064469v1 | N/A | Glucocorticoids | To systematically retrieve and summarize the current evidence of the effectiveness and safety of glucocorticoid therapy for patients with COVID-19 |
| 26 April 2020 | MedRxiv | A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections | Systematic review | UK | Khan et al | https://www.medrxiv.org/content/10.1101/2020.04.23.20076612v1.full.pdf | N/A | Anakinra, Tocilizumab, Sarilumab, Siltuximab | To assess the effectiveness of specific interleukin-1 and -6 inhibitors for the treatment of coronavirus-related infections. |
| 13 April 2020 | Press release | Southern California Patients Treated with Leronlimab for COVID-19 under Emergency IND | Preliminary results from clinical trial | USA | CytoDyn INC. | https://www.cytodyn.com/newsroom/press-releases/detail/415/southern-california-patients-treated-with-leronlimab-for | NA | leronlimab | Could leronlimab be effective? |
| 28 February 2020 | Aging and Disease | Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia | CT | China | Leng et al. | http://dx.doi.org/10.14336/AD.2020.0228 | ChiCTR2000029990 | ACE2-mesenchymal stem cell | Efficacy of MSC transplantation in COVID patients |
| 26 March 2020 | Journal of Medical Virology | Tocilizumab treatment in COVID-19: a single center experience | Observational study | China | Luo et al. | https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25801 | NA | tocilizumab | What are treatment responses of TCZ in the COVID-19 patients? |
| 17 April 2020 | Circulation Research | Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Observational study | China | Zhang et al. | https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.120.317134 | NA | Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin receptor blockers (ARBs) | To determine the association between in-hospital use of ACEI/ARB and all-cause mortality in COVID-19 patients with hypertension |
| 23 April 2020 | JAMA | Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection inWuhan, China | Case series | China | Juy Li, et al | https://jamanetwork.com/journals/jamacardiology/fullarticle/2765049 | NA | Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin receptor blockers (ARBs) | Asses the association between ACEIs/ARBs and severity of illness and mortality in patients with hypertension hospitalized for COVID-19 infection. |
| PrePrint | Acta Pharmaceutica Sinica B | Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19 | RCT | China | Xiaoyan Liu, et al. | https://www.sciencedirect.com/science/article/pii/S2211383520305529 | NA | Dipyridamole | Is treatment with dipyridamol clinically effetive in severly ill COVID19 patients? |
| 18 April 2020 | medRxiv | Benefits and Risks of Chloroquine and Hydroxychloroquine in The Treatment of Viral Diseases: A Meta-Analysis of Placebo Randomized Controlled Trials | meta-analysis of RCTs | China/ USA | Jing Wang et al | https://www.medrxiv.org/content/10.1101/2020.04.13.20064295v1.full.pdf | | chloroquine/hydroxychoroquine | To evaluate the efficacy and safety of Chloroquine and hydroxychloroquine |
| 20 April 2020 | medRxiv | Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 2 - Hand hygiene and other hygiene measures: systematic review and meta-analysis. | systematic review and meta-analysis | Saudi Arabia, Australia, Canada | Al-Ansary | https://www.medrxiv.org/content/10.1101/2020.04.14.20065250v1.full.pdf | NA | hygiene interventions | To assess the effectiveness of hand hygiene, surface disinfecting, and other hygiene interventions in preventing or reducing the spread of illnesses from respiratory viruses |
| 17 April 2020 | medRxiv | An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area | Clinical trial | China | Meng et al. | https://www.medrxiv.org/content/10.1101/2020.04.11.20061473v1.full.pdf | NCT04320238 | Recombinant human interferon-alpha nasal drops | To investigate the efficacy and safety of recombinant human interferon alpha1b (rhIFN-α) nasal drops in healthy medical staff to prevent COVID-19. |
| 23 March 2020, updated 15 April 2020 | medRxiv | An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI) | RCT | China | Li et al. | https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v2.full.pdf | NCT04252885 | lopinavir/ritonavir (Kaletra), arbidol | Lopinavir-Ritonavir combination compared to Arbidol compared to no antiviral treatment |
| 17 April 2020 | medRxiv | Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis | review and meta-analysis | China | Shi et al. | https://www.medrxiv.org/content/10.1101/2020.04.13.20064436v1.full.pdf | NA | antivirals | To assess the potential effectiveness and safety of antiviral agents for COVID-19 in children. |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 17 April 2020 | medRxiv | Efficacy and Safety of Antibiotic Agents in Children with COVID-19: A Rapid Review | rapid review | China | Wang et al | https://www.medrxiv.org/content/10.1101/2020.04.13.20064402v1.full.pdf | NA | antibiotics | The aim of this review was to evaluate the efficacy and safety of antibiotic agents in children with COVID-19 |
| Preprint | Médécine et Maladies Infectieuses | No evidence of rapid antiviral clearance or clinical ben-efit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection | Prospective virological assay | France | JM Molina et al. | https://www.sciencedirect.com/science/article/pii/S0399077X20300858?via%3Dihub | NA | Hydroxychloroquine, azithromycin | Is hydroxychloroquine effecitve for viral clearance when reproducing the study of Gautrel et al.? |
| Accepted 31 March 2020 | Journal of Infection | The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis | Meta-analysis | China | Zhenwei Yang, et al. | https://www.sciencedirect.com/science/article/pii/S0163445320301912?via%3Dihub | Grant from the National Natural Science Foundation of China (Jing Liu, grant no. 81472735 ) and the Wuhan University (Jing Liu, grant no. 2042019kf0206 | Corticosteroids | Evaluate the influence of corticosteroids in patients with coronavirus. |
| Preprint | Clinical Infectious Diseases | Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients | Prospective PK study | France | Sophie Perinel et al, | https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa394/5816960 | NA | Hydroxychloroquine | What is the best dose of hydroxychloroquine for COVID19 patients? |
| | Journal of Molecular Cell Biology | Treating COVID-19 with Chloroquine | RCT | China | Mingxing Huang, et al. | https://academic.oup.com/jmcb/article/doi/10.1093/jmcb/mjaa014/5814655 | NA | Chloroquine, lopinavir, ritonavir | Is cholorquine better than lopinavir/ritonavir in severe and moderate COVID19 patients? |
| 10 April 2020 | NEJM | Compassionate Use of Remdesivir for Patients with Severe Covid-19 | Report | UK, Canada, Europe, Japan | Grein et al. | https://www.nejm.org/doi/full/10.1056/NEJMoa2007016 | NA | Remdesivir | NA |
| 10 March 2020 | Journal of Critical Care | A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 | Systematic review | Italy | Andrea Cortegiani, et al. | https://www.sciencedirect.com/science/article/pii/S0883944120303907?via%3Dihub | NA | Chloroquine | Summary of the existing the evidence on chloroquine for the treatment of COVID-19 |
| Preprint | Journal International AIDS Society | Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS, or COVID-19: initial assessment | Systematic review | Switzerland | N Ford et al. | https://onlinelibrary.wiley.com/doi/10.1002/jia2.25489 | NA | Antiretroviral drugs | Systematic review of the clinical outcomes of using antiretroviral drugs for the prevention and treatment of coronaviruses and planned clinical trials |
| 30 March 2020 | Complementary Therapies in Clinical Practice | Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study | Non-interventional RCT | China | Kai Liu, et al. | https://www.sciencedirect.com/science/article/pii/S1744388120304278 | Ethics committees of Hainan General Hospital and Huanggang Central Hospital (approval numbers: 19758 and 20200125) | Respiratory rehabilitation training | Investigate the effects of 6-week respiratory rehabilitation training on respiratory function, QoL, mobility and psychological function in elderly patients with COVID-19 |
| 6 March 2020 | Complementary Therapies in Clinical Practice | Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19 | Non-interventional RCT | China | Kai Liu, et al. | https://www.sciencedirect.com/science/article/pii/S1744388120302784 | NA | Progressive muscle relaxation (sleep therapy) | Investigate the effect of progressive muscle relaxation on anxiety and sleep quality of COVID-19 patients |
| 24 March 2020 | MedRxiv | First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients | CT | China | Chen et al. | https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1.full.pdf | NCT04291729 | danopevir/ritonavir | Effect of danoprevir in moderate COVID-19 patients |
| 07 April 2020 | MedRxiv | The potential of low molecular weight heparin to mitigate cytokine storm in severe covid-19 patients: a retrospective clinical study | Retrospective CT | China | Chen Shi et al. | https://www.medrxiv.org/content/10.1101/2020.03.28.20046144v2 | not found | enoxaparin | Efficacy of enoxaparin |
| 14 April 2020 | MedRxiv | No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial | Retrospective analysis | France | Matthieu Mahévas et al. | https://www.medrxiv.org/content/10.1101/2020.04.10.20060699v1.full.pdf | NA | Hydroxychloroquine | To assess the effectiveness of Hydroxychloroquine in patients with severe Covid-19 |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 27 March 2020 | JAMA | Treatment of 5 critically ill patients with COVID-19 with convalescent plasma | Observational study | China | C Shen, et al. | https://jamanetwork.com/journals/jama/fullarticle/2763983 | Grants: National Science and Technology Major Project (2018ZX10711001, 2017ZX10103011, 2017ZX10204401), Sanming Project of Medicine in Shenzhen (SZSM201412003, SZSM201512005), China Postdoctoral Science Foundation (2019T120147, 2018M641508), Shenzhen Science and Technology Research and Development | Convalescent plasma | Is plasma from convalescente patients beneficial for critically ill COVID19 patients? |
| 6 April 2020 | Proceedings of the National Academy of Sciences of the United States of America | The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study | Observational/retrospective control | China | Kai Duan et al | https://www.pnas.org/content/early/2020/04/02/2004168117 | ChiCTR2000030048 | Convalescent plasma | Is treatment with convalescent plasma safe and beneficial for COVID19 patients? |
| Preprint | Influenza and other Respiratory Viruses | Medical Masks vs N95 Respirators for Preventing COVID-19 in Health Care Workers - A Systematic Review and Meta-Analysis of Randomized Trials | Systematic review | Canada | Jessica J Bartoszko, et al. | https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.12745 | NA | N95 respirators vs surgical masks | Compare medical masks to N95 respirators in preventing laboratory confirmed viral infection and respiratory illness including coronavirus specifically in health care workers. |
| Preprint | Disaster Medicine and Public Health Preparedness | RANDOMIZED TRIAL OF INSTRUCTOR-LED TRAINING VERSUS VIDEO LESSON IN TRAINING HEALTH CARE PROVIDERS IN PROPER DONNING AND DOFFING OF PERSONAL PROTECTIVE EQUIPMENT | RCT | Denmark | L Christensen et al | https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/article/randomized-trial-of-instructorled-training-versus-video-lesson-in-training-health-care-providers-in-proper-donning-and-doffing-of-personal-protective-equipment/CF08F4727DA9D536883ECBFD04BC2570 | NA | Training on personal protective equipment | Is attending one live training session or watching video trainings over a month more effective for training on downing and doffing personal protective equipment? |
| Preprint | Journal of Medical Virology | Performance of VivaDiagTM COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department | Diagnostic assay | Italy | Irene Cassantini et al. | https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25800 | NA | Diagnostic serological assay | To assess an easy to perform serological assay for diagnosis of COVID19 |
| Preprint | Joural of Clinical Microbiology | Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2 | Diagnostic assay | China | Wanbing Liu, et al. | https://jcm.asm.org/content/early/2020/03/27/JCM.00461-20 | DOI: 10.1128/JCM.00461-20; Hospital Ethics Committee of the General Hospital of the Central Theater Command 107 of the PLA ([2020]003-1) | Diagnostic serological assay | Evaluate the diagnostic feasibility of two ELISA assays |
| Article originally published in 2015; authors added comment on 30/03/2020 | BMJ Open | A cluster randomised trial of cloth masks compared with medical masks in healthcare workers | RCT | Australia /Vietnam | MacIntyre CR et al. | https://bmjopen.bmj.com/content/5/4/e006577 | Australian New Zealand Clinical Trials Registry: ACTRN12610000887077. | medical masks, cloth masks | To compare the efficacy of cloth masks to medical masks in hospital healthcare workers |
| 31 March 2020 | MedRxiv | Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial | RCT | China | Zhaowei Chen et al. | https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2 | ChiCTR2000029559 | Hydroxychloroquine | Assess the efficacy of hydroxychloroquine |
| Preprint | | Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study | RCT | France | Gautret et al. | https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf | NA | Hydroxychloroquine, Azithromycin | Assess the efficacy of hydroxychloroquine associated with azithromycin |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| 23 March 2020 (preprint, not yet peer-reviewed) | BMJ | An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI) | RCT | China | Li et al. | https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1 | NCT04252885 | lopinavir/ritonavir (Kaletra), arbidol | Lopinavir-Ritonavir combination compared to Arbidol compared to no antiviral treatment |
| 10 Feb 2020 | Biosci Trends | Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. | Summary of 15 CTs | China | Gao et al. | https://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01047/_article | ChiCTR2000029939, ChiCTR2000029935, ChiCTR2000029899, ChiCTR2000029898, ChiCTR2000029868, ChiCTR2000029837, ChiCTR2000029826, ChiCTR2000029803, ChiCTR2000029762, ChiCTR2000029761, ChiCTR2000029760, ChiCTR2000029740, ChiCTR2000029609, ChiCTR2000029559, and | Chloroquine | Could chloroquine be effective? |
| 30 March 2020 | not published yet | Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients | Preliminary results from clinical trial | USA | CytoDyn Inc. | https://www.cytodyn.com/newsroom/press-releases/detail/401/three-additional-patients-with-severe-covid-19-treated-with | NA | Leronlimab | Could leronlimab be effective? |
| 27 March 2020 | medRxiv | Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial | RCT | China | Chang Chen et al. | https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2 | ChiCTR2000030254 | Favipiravir, Arbidol | Conventional therapy + favipiravir or arbidol? |
| 20 March 2020 | International Journal of Antimicrobial Agents | Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial | CT | France | Gautret et al. | https://www.sciencedirect.com/science/article/pii/S0924857920300996#! | EudraCT number 2020-000890-25 | Hydroxychloroquine, Azithromycin | Role of hydroxychloroquine on respiratory viral loads |
| 19 March 2020 | N Engl J Med | A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. | RCT | China | Cao et al. | https://www.ncbi.nlm.nih.gov/pubmed/32187464 | ChiCTR2000029308 | lopinavir/ritonavir (Kaletra) | Lopinavir-Ritonavir combination compared to conventional therapy ? |
| 11 March 2020 | Journal of Infection | Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study | Retrospective cohort study | China | Lisi Deng | https://www.sciencedirect.com/science/article/pii/S0163445320301134?via%3Dihub | NA | Lopinavir/ritonavir, Arbidol | Arbidol and lopinavir-ritonavir compared to lopinavir-ritonavir only? |
| In press | British Journal of Anaesthesia | High-flow nasal-oxygenation- assisted fibreoptic tracheal intubation in critically ill patients with COVID-19 pneumonia: a prospective randomised controlled trial | RCT | China | Cai-Neng Wu et al. | https://bjanaesthesia.org/article/S0007-0912(20)30135-5/fulltext | ChiCTR2000029658 | High-flow nasal oxygnation | What is the efficacy and safety of high-flow nasal oxygenation during fibreoptic bronchoscopic intubation in critically ill patients with COVID-19? |
| 2020 Pre-print online | Chinese Journal of Infectious Diseases, | Efficacy of lopinavir, ritonavir and Arbidol for the treatment of new coronavirus pneumonia | Retrospective analysis | China | Chen Jun et al. | http://rs.yiigle.com/yufabiao/1182592.htm | NA | Lopinavir/ritonavir, Arbidol | Efficacy of lopinavir/ritonavir and arbidol |
| 2020 | Journal of Zhejiang University (Medical Science) 2020 , Vol. 49 Issue (1) | A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) | RCT | China | Chen Jun et al. | http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.03.03 | NCT04261517 | Hydroxychloroquine | Role of hydroxychloroquine on respiratory viral loads |
| 2020 Pre-print | MedRxiv | Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial | CT | China | Huijie Bian et al. | https://doi.org/10.1101/2020.03.21.20040691 | NCT 04275245 | Meplazumab | Assess the efficacy and safety of meplazumab, a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia. |
| | | | | | | | | | |
| | | | | | | | | | |
| Total | | | | | | | | | |